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ABSTRACT
Neuropeptide FF is an endogenous RF-amide with two receptor subtypes originally
described as having anti-opioid characteristics. While peptide work helped to elucidate key
features for targeting the subtypes of the neuropeptide FF receptor, non-peptide small molecules
offer a more refined tool to discover features that affect selectivity and affinity. Improvements in
small molecule ligands for neuropeptide FF support lead development and offer a clearer
understanding of the binding pocket of each receptor subtype. Previous work on the lead 4anilindopiperidine structure clarified a key feature between agonist and antagonist behavior.
Early modifications of substituents of the piperidine nitrogen were tolerated and created selective
ligands. Therefore, syntheses of aliphatic and aromatic substitutions of the piperidine nitrogen of
a 4-anilinopiperdine lead molecule were conducted. In vitro evaluation of the novel compounds
was conducted through a collaborator. Binding affinities of the novel compounds were
determined through displacement of a radioligand ([3H]-NPVF for NPFF1 receptors and [3H]EYF for NPFF2 receptors) and were conducted for each subtype. Though some of the
compounds, such as cycloheptylmethyl substituted analog, did not bind within the limits of the
assay to either subtype, other compounds, such as the cyclopropylmethyl and methylindole
derivatives, did bind. The cyclopentylmethyl and methylindole derivatives offered a weak
preference for the second subtype.
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The formalin assay offers an opportunity to evaluate neuropeptide FF in a tonic pain model. In
summation, selective non-peptide ligands for each neuropeptide FF receptor offer a key tool to
elucidating the evolving role of neuropeptide FF and creating potentially useful therapeutics in
the future.
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CHAPTER 1
INTRODUCTION

With the discovery and isolation of neuropeptide FF (NPFF) from bovine brain in 1985 1,
NPFF (FLFQPQRFa) has been linked to a variety of biological activities. It is part of a family of
peptides that have a dipeptide Arg-Phe-NH2 at their C-terminal, known as RF-amides2. Other
members of the family include prolactin-releasing peptides, kisspeptin/metastin and
QRFP/P518/26RFa3. Two subtypes of the G protein-coupled receptor for NPFF exist and have
been identified as NPFF1 and NPFF24. Endogenous peptides NPSF and NPVF show preference
for NPFF1 subtype in vivo5, while endogenous peptide NPFF prefers NPFF2 subtype6. Table 1
describes the sequences of NPSF, NPVF, and NPFF for human, bovine, mouse, and rat species6.
NPFF1 and NPFF2 are distributed throughout the body with NPFF2 present in both the spine and
brain, while NPFF1 appears only in the brain7, 8.

1

Table 1 Sequence of endogenous neuropeptide FF and RF-related peptides

a

Note that NPSF has been used in the literature to describe both an eight amino acid short version
of NPAF and a 37 amino acid extended version of rat RFRP-1. NPFF: neuropeptide FF; RFRP:
RF-related peptide. Reproduced with permission from 6.
Although initially described solely as an anti-opioid system9, 10, NPFF through its
interaction with its cognate receptors exhibits a myriad of pharmacological effects. The complex
nature of the NPFF pharmacology depends on which subtype is targeted, the route of
administration, and opioid activity11. For example, the anti-opioid properties of NPFF are seen
when the route of administration is intracerebroventricular (i.c.v.); yet, if the route of
administration is changed to intrathecal (i.t.), NPFF has shown to extend morphine-induced
analgesia12. In addition to affecting the opioid system, NPFF has been connected to pain
modulation, changes in arterial blood pressure8, regulation of monoamine systems8, reduction in
food intake13, 14 and regulation of core temperature15, 16. The majority of the pharmacological
functions have been discovered through several groups’ efforts to create peptide ligands for
NPFF1 and NPFF2 receptors.

2

Initial work in the 1990s observed the importance of the N-terminal amino acids of
endogenous NPFF by the creation of modified peptide analogs17. It was initially shown that the
N-terminal amino acid was responsible for high affinity binding. Affinity radioligands for NPFF
receptors were created by modifying peptides (DYLMEFQPQRF- and YLFQPQRF-amide)18.
Peptide synthesis and subsequent evaluation produced both agonist and antagonists. BIBP3226
was initially described as a neuropeptide Y (NPY) Y1 receptor antagonist 19, 20. It also proved to
have pharmacological activity at NPFF receptors both in vitro and in vivo. For example, in vitro
NPY-derived ligands BIBP3226 (Ki ≈ 100nM for NPFF2 receptor) and GR231118 (Ki = 50-70
nM for NPFF2 receptor) acted as antagonist, and agonist, respectively21. In vivo BIBP3226 was
able to offset hypothermic effects of cerebrally injected NPFF and NPVF in mice and prevent
anti-morphine actions of NPFF in mouse tail-flick assay22. By contrast, it appears that the
endogenous peptide NPVF is selective for NPFF1 versus NPFF2 receptors5. Likewise, peptide
VPNLPQRF-NH2 shows strong selectivity for the NPFF1 receptor, while peptide
EFWSLAAPQRF-NH2 has strong selectivity for the NPFF2 receptor (Table 2)23.
Table 2 Peptides with selectivity for NPFF 1 or NPFF2
Peptide Sequence

Ki for NPFF1 (nM)

Ki for NPFF2 (nM)

VPNLPQRF-NH2

0.6

17.4

EFWSLAAPQRF-NH2

20.8

0.21

Data from 23.
The dipeptide known as RF9 is a nonselective antagonist for the NPFF receptors (Figure
1)24. RF9 can prevent NPFF-induced hypothermia25 and does not lower body temperature itself.
RF9 does appear to exert inhibitory effects on NPFF agonist-induced changes in body
temperature and nociceptive tests, yet does not affect these changes when administered alone 26.
3

Figure 1 Nonselective dipeptide neuropeptide FF antagonist, RF9

Another interesting study showed that dansylated GSRF-NH2 and dansylated PQRF-NH2
acted as agonists, while dansylated GSR-NH2 and dansylated PQR-NH2 acted as antagonists on
NPFF receptors16, 27. More recently, the peptide dNPA (D-Asn-Pro-(NHMe)Ala-Phe-Leu-PheGln-Pro-Gln-Arg-Phe-NH2) was found to be a selective NPFF2 agonist28.
Found mainly in the patent literature, non-peptide small-molecule NPFF ligands offer a
different viewpoint for probing the NPFF receptors and pharmacology of the system as a whole.
One of the main benefits of these small-molecule ligands is their ability to better define the
active site of NPFF1 or NPFF2 receptors; likewise, selectivity and affinity can be improved
through relatively minor modifications in a parent structure. The majority of the small molecules
described in the patent literature feature a guanidine functionality. For instance, Acadia
Pharmaceuticals has published structures featuring hydrazine/guanidine functionality; Actelion
Pharmaceuticals and Synaptic Pharma Group each published similar core structures with a
guanidine moiety attached directly to a heterocycle (Figure 2 & 3). In contrast, two different
Japanese patents show molecules that do not have a guanidine moiety but still retain their affinity
for NPFF system.
4

Figure 2 Actelion Pharmaceuticals compounds with single digit nanomolar IC50 at NPFF1
receptor

Figure 3 Synaptic Pharma Group NPFF core structures

Taisho Pharmaceutical, a Japanese company, has a patent 29 that describes compounds
with IC50 values between 30 and 300 nM. The IC50 values are for rat NPFF2 receptors in vitro.
The core structure of their compounds is represented by a fused imidazole-pyrazine with indole
and piperidine substitutions (Figure 4).

5

Figure 4 Core structure for Taisho Pharmaceutical NPFF 2 compounds

R=

Examples of substitutions (not inclusive) from Taisho Pharmaceutical 29.
The structure-activity relationship (SAR) suggests that varying the carbon linker between
the piperidine nitrogen and a substitution is tolerated within the reported IC 50 values (Figure 5).
Figure 5 Changes in carbon linker between piperidine nitrogen and alkyne moiety

6

Likewise, methylation at various positions of indole ring maintains activity within the 30300 nM range (Figure 6). Attachment of indole-substituted electron-withdrawing or electrondonating groups also preserves activity (Figure 6).
Figure 6 Various substitutions on the indole ring

Changing the piperidine ring nitrogen substituent to a secondary or tertiary amine, or
having an ether linkage still upholds IC50 values in the reported range. Replacing the indole ring
with other heterocyclic ring systems also keeps the IC50 values between 30 and 300 nM. While
Taisho Pharmaceutical describes over 90 compounds in their patent, specific IC50 values for
individual compounds are not disclosed. Therefore, it is difficult to fully appreciate and
construct a complete SAR.
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Kyowa Hakko Kogyo Company reports their NPFF small molecules at a fixed
concentration 3 µM and as a percentage binding of rat NPFF receptor30. These molecules have
an indole ring with a four carbon spacer attached to a pyrrolidine as their common core
structure (Figure 7).
Figure 7 Core Structure of Kyowa Hakko Kogyo NPFF small molecule ligands

R

R1

20

21

22

This is not an inclusive list of R and R1 substitutions included in the patent 30.

8

The best compound disclosed has a branched biphenyl in the 3-position and a
cyclooctane ring in addition to the core structure (Figure 8). This compound exhibits 100%
binding at 3µM. Interestingly, replacing the cyclooctane ring with a cyclohexane ring reduces
the percent binding by almost 40%, to 61% at rat NPFF receptor (Figure 9). Changing a
cyclohexane to a cycloheptane ring improves the percentage binding to approximately 94%.
Another interesting finding from the SAR study is the importance of the linker between the
indole and pyrrolidine, switching from a four-carbon linker to a three-carbon linker drops the
activity from 100% to 41% binding at 3 µM.
Figure 8 Best Kyowa Hakko Kogyo compound

100% binding at 3 µM at rat NPFF receptor.

9

Figure 9 Different Ring Sizes in Kyowa Hakko Kogyo Compounds

Varying ring size from an eight- to six- member ring dramatically decreases percent binding to
rat NPFF receptor.

The change in linker does not always decrease percentage binding; in fact, reducing the
linker from a four- to three-carbon chain improves percentage binding. While certain SAR
features are clearer with Kyowa Hakko Kogyo compounds, further clinical development seems
unlikely due to high lipophilicity of these compounds. Delivery, drug-drug interactions and
plasma-protein binding all seem plausible barriers to development of these NPFF small
molecules. Some of these challenges may have already been addressed, as the patent reports that
in vivo hot plate and tail-flick assays were performed; however, it was unclear which compound
or compounds were tested.
Acadia Pharmaceuticals published selective NPFF2 receptor agonists with a hydrazineguanidine core structure31. They report their data as pEC50 and percentage efficacy for NPFF1
and NPFF2 receptors, although they do not specify from which species the NPFF receptors are
derived. According to the patent32, efficacy is the percentage maximal response compared with
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the maximum response elicited by endogenous neuropeptide FF; therefore, pEC 50 is the negative
log(EC50) and the EC50 is the molar concentration that produces 50% maximal response. A
variety of substitutions of the hydrazine-guanidine core provided active and selective
compounds. Of the compounds tested in vitro at both NPFF1 and NPFF2 receptors, two were
taken on further to in vivo models of pain (Figure 10).
Figure 10 Compounds from Acadia Pharmaceuticals

Compounds 1045, 3093, and 3099 are selective NPFF2 receptor agonists; Compounds 3093 and
3099 were successful at reducing tactile allodynia in spinal nerve ligation model of pain in rats.

Compound 25 was tested in thermal hyperalgesia assay and chronic constriction injury
assay33, 34 where it showed dose-dependent reduction in hyeralgesia. Interestingly, compound 24
with a dichlorobenzylidene fragment was not effective in multiple in vivo models; yet compound
25 with the dibromobenzylidene residue was effective in some of the same in vivo models of
pain and inflammation. In addition, compound 26 with a chlorotrifluromethylbenzylidene
moiety was also effective in in vivo models.

11

Actelion Pharmaceuticals disclosed compounds exhibiting nanomolar binding to NPFF1
receptor expressed in Chinese hamster ovary (CHO) cells. The core structure is a
tetrahydroquinazoline with a guanidine at the 2-position and a methyl at the 4-position35. The
disclosed compounds with the 2-guanidine, 4-methyl tetrahydroquinazoline core structure and an
aliphatic substitution of at least two carbons at the 6-position have single-digit nanomolar
binding affinities (Figure 2). In a second patent36, Actelion Pharmaceuticals describe
compounds having a tetrahydrobenzothiazole with a guanidine at the 2-position. Nanomolar
binding for NPFF1 receptor is reported for several of their best compounds. Substitutions at the
5-, 4-, and 6-position were explored and are tolerated maintaining single-digit binding affinity.
A few interesting SAR features were identified through exploration of substitutions around the
tetrahydrobenzyl portion of the compound. For example, a tert-butyl group at the 6-position
affords 10 nM affinity, yet moving it to the 4-position creates an even stronger binding affinity at
2 nM (Figure 11).
Figure 11 Positional Isomers from Actelion Pharmaceuticals

Changing a tert-butyl substitution from the 6- to the 4-position increases NPFF1 receptor binding
affinity.
Similarly, changing a dimethyl substitution from the 6-position to the 5-position of the
tetrahydrobenzothiazole ring improves the binding from 4 to 2 nM, while changing a methyl,
ethyl di-substitution from the 4- to the 5-position increases the binding from 5 to 0.2 nM (Figure
12).
12

Figure 12 Explorations of Tetrahydrobenzothiazole Ring Substitutions

Changes from the 6- or 4-position to the 5-position on the tetrahydrobenzothiazole ring improves
binding affinity at NPFF1 receptor.

While these data prove interesting, it is difficult to know how selective the compounds
from Actelion Pharmaceuticals are, since no NPFF2 receptor data are presented in the patents.
Synaptic Pharma Group describes compounds that are agonists, antagonists and mixed
agonist/antagonists at NPFF1 and NPFF2 receptors. They describe compounds in both rat and
human NPFF1 and NPFF2 receptor binding. The core structure of their compounds are a
quinazoline with a guanidine at the 2-position and a methyl substitution at the 4-position37, 38
(Figure 3). Aliphatic and aromatic substitutions at the 6- and 7-position were explored. Larger
aliphatic or bicyclic substitutions seem to create compounds that bind to NPFF1 and NPFF2
receptors without much selectivity; while smaller substitutions at the 6- or 7-position create
compounds with at least tenfold selectivity between the two receptor subtypes. The company
describes their compounds as agonist or antagonist according to intrinsic activity and Ki values:
an agonist has a >15% intrinsic activity, an antagonist has ≤15% intrinsic activity and a Ki value
≤1.2 µM at the rat NPFF receptors39. According to Synaptic Pharma Group’s claims,
compounds that act as an agonist at NPFF1 and NPFF2 receptors would be suitable for treatment
13

of incontinence and pain; likewise, compounds that as NPFF1 and NPFF2 receptor antagonists
could have pro-opioid effects. Additionally, compounds that are NPFF1 receptor agonists might
be used to treat obesity, according to the company’s patents39.
Despite a variety of small molecules published in patent literature, a straightforward SAR
is still absent. Lipophilic substitutions, a nitrogen-containing heterocycle, and guanidine
substitution are common to most but not all of structures.

14

CHAPTER 2
PRELIMINARY DESIGN OF NON-PEPTIDE NEUROPEPTIDE FF LIGANDS

Initial work on non-peptide ligands for neuropeptide FF began with an assessment of the
structure-activity relationships (SAR) learned from neuropeptide FF peptide work 40 and lessons
learned in the opioid field41-43. For instance modifications on both the C-terminal and N-terminal
of endogenous neuropeptide FF lead to the conclusions that the N-terminal was responsible for
high affinity binding17 while the C-terminal showed the importance of the guanidine and
aromatic functionalities40, 44. Furthermore work within opioid analgesics demonstrates the 4anilindopiperdine (Figure 13) to be a relevant and chemically feasible starting point for a nonpeptide neuropeptide FF ligand45. Overlay of the 4-anilindopiperdine structure shows that key
features could be aligned with endogenous NPFF C-terminal features of a guanidine and an
aromatic ring (Figure 14)40. These facts guided the design and evaluation of various portions of
the 4-anilindopiperdine core to optimize affinity and selectivity for both NPFF receptor subtypes.
Figure 13 Representative 4-anilindopiperide opioid analgesics, Fentanyl
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Figure 14 Alignment of guanidine substituted 4-anilinopiperdine and neuropeptide FF

The guanidine substitution aligns with the arginine residue of the peptide and the aromatic rings
align with phenylalanine rings of the peptide.40

Work began on the 4-anilindopiperdine core with modifications occurring in three
locations: the aniline moiety (A), the nitrile moiety (B), and the piperidine nitrogen (C) (Figure
15).
Figure 15 Three key locations of modification for non-peptide neuropeptide FF ligands

A

C
B
34
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Starting with the aniline moiety (A) modifications explored the space of the binding
pocket near the aniline portion by adding electron-withdrawing groups such as halides (F and Cl)
or electron-donating groups such as methoxyl in various substitution patterns.
These changes did not improve selectivity between NPFF1 and NPFF2 receptors but gave
affinity in the hundreds nanomolar range in a competitive radioligand binding assay46. In
another modification the aniline moiety was replaced with a naphthalene-1-amine. This structure
had improved binding at NPFF1 compared to earlier structures and had a ten-fold selectivity at
NPFF1 compared to NPFF2. To see if the aniline moiety was necessary, compounds were
synthesized without the aniline. The resulting compounds showed weak binding to NPFF2 and
did not displace the radioligand within the limits of the assay for NPFF1. To further understand
if the nitrogen of the aniline was necessary for binding an analog was synthesized with a benzyl
substitution. Likewise, instead of a naphthalene-1-amine, a naphthalene analog was also
synthesized. In both cases, loss of the nitrogen did not decrease binding affinity but switched the
relative selectivity; in other words the analog with the nitrogen was selective for NPFF1 receptor
while the analog without the nitrogen was selective for NPFF2 receptor (Figure 16). Some
changes to the aniline moiety were also combined with or caused changes in the nitrile
(guanidine) portion of the core structure. For instance, a 2-phenyl-benzylimidazole substitution
attempted to mimic the aniline portion but also rigidify the guanidine/nitrile portion of the core
structure. The resulting compound yielded no selectivity between the receptor subtypes and poor
binding (five- to six-thousand nanomoloar). Similarly having an amide bond in lieu of the
aniline as well as a medium (4-carbon) chain to the guanidine moiety gave poor binding at
NPFF2 and no binding at NPFF1. In another attempt to explore the importance of the aniline an

17

amide bond was introduced; this structure also had a 4-carbon spacer to the guanidine. The
changes did not lead to a selective ligand and it had poor binding affinity.
Figure 16 Modifications in aniline moiety of core structure

Modifications of aniline and nitrile/guanidine moieties together did not yield favorable
results. To examine the potential benefits of modifying the nitrile/guanidine (Figure 15, B) a
variety of changes were made. One change was to see if a permanent charge would improve
affinity or selectivity as the guanidine is ionized at physiologically relevant pHs. The
permanently charged compound did not bind within the limits of the assay. Another change
made was to create a reverse amide; this compound gave hundred-fold selectivity for NPFF1
versus NPFF2 receptor (Figure 17).
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Figure 17 Reverse amide NPFF ligand

Initially the core structure contained a guanidine group directly attached to the piperidine ring,
and compounds were designed to contain a spacer between the piperidine and guanidine groups.
The most logical compound incorporated arginine, as this amino acid contained a guanidine
moiety. The arginine derivative provided ten-fold selectivity toward the NPFF1 receptor; while
eliminating the primary amine leaving only a 3-carbon spacer abolished the selectivity between
NPFF1 and NPFF2 receptors. Moreover increasing the spacer to 4- or 5- carbons did not confer
selectivity or improve affinity. In contrast, decreasing the spacer between the piperidine ring and
the guanidine moiety to a glycine amino acid giving a one carbon spacer or moving to a two
carbon spacer did improve selectivity for NPFF1 receptor over NPFF2 receptor (Figure 18).
Rigidifying the linker from a simple carbon chain to a benzyl linker did not enhance selectivity
or affinity. Attempts to alter the guanidine moiety to a more orally bioavailable and
physiologically acceptable structure did not result in complete loss of affinity but failed to confer
greater than ten-fold selectivity for NPFF1 versus NPFF2 receptors (Figure 19).
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Figure 18 Changing from arginine to glycine linker to guanidine moiety

Figure 19 Alternations of the guanidine moiety

Initially the arginine residue at position B of the core structure was kept constant while
modifications of the piperidine-ring nitrogen were explored. For example, switching from a
benzyl to a methyl group provided an analog with no activity at the maximal concentration of the
binding assay. Likewise, extending the linker from one carbon to two carbons between the
piperidine nitrogen and the benzyl ring did not improve selectivity. A ten-fold selectivity for
NPFF1 receptor was achieved when the piperidine nitrogen was substituted with a bi phenyl
moiety. Finally a naphthalene substitution improved binding affinity at both receptors but did
not improve selectivity between the receptor subtypes (Figure 20).
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In a parallel series no

spacer was utilized to separate the guanidine moiety from the core piperidine structure.
Expanding the space by two carbons between the piperidine nitrogen and the benzyl moiety did
not improve selectivity or affinity compared to the simple benzyl substituted compound.
Likewise, changing to a methyl gave no affinity for either receptor even at the maximal
concentration of the binding assay.
Since earlier work at position B of the core showed that a glycine spacer from the core
structure to the guanidine moiety provided good affinity, this was utilized as the new standard for
the remaining modifications to substitutions of the piperidine nitrogen. For instance an ethyl
benzyl substitution gave a ten-fold selectivity to NPFF2 receptor versus NPFF1 receptor. The
naphthalene substitution gave good affinity but did not confer selectivity between the two
receptor subtypes. Moreover, a positional isomer of the naphthalene substitution also had good
affinity but selectivity again was not improved. Creating a mimic for the naphthalene with an Ecinnamyl substitution followed the trend of good affinity, but no distinct selectivity between
receptor subtypes (Figure 21).
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Figure 20 Early substitutions at the piperidine nitrogen with arginine-guanidine core
structure

Figure 21 Glycine-guanidine core structure with various piperidine nitrogen substitutions
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Other modifications include mono- and di-substituted aromatic substitutions.
Compounds containing mono-substitutents at para-, ortho-, and meta-positions were
synthesized. Electron-withdrawing groups at the para-position had good affinity for NPFF1 and
NPFF2 receptors. Electron-withdrawing group at the ortho-position maintained good affinity
(hundreds nanomolar) but did not show selectivity. An electron-withdrawing group at the metaposition actually decreased affinity by ten-fold. However, an electron-donating group at the
meta-position kept affinity in the hundred nanomolar range. Di-substitutions on the aromatic
ring off the piperidine nitrogen gave good affinity in the case of meta-, para-substitution pattern.
In the case of both meta-positions being occupied a ten-fold selectivity was afforded to NPFF2
versus NPFF1 receptors.
A ten-fold selectivity was also produced when the position of the nitrogen on the
piperidine was changed so the aniline and guanidine moieties were now only one carbon
compared to the normal two carbons away (Figure 22). The isoelectric replacement of the
nitrogen with a double-bond did not enhance the affinity or selectivity. Likewise changing from
benzene to pyridine did not improve selectivity or affinity for the NPFF receptors.
Figure 22 Change in position of nitrogen of piperidine ring to aniline/guanidine portion of
core structure
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Positional isomers of the pyridine substitution may offer different perspective and have
been synthesized. In contrast, a cyclohexane replacement of the benzene ring provided a ten-fold
selectivity toward NPFF2 compared to NPFF1 receptors. The goal of this work was to explore
further aliphatic substitutions of various sizes to better understand their potential impact on
affinity and selectivity in the lead template molecule.
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CHAPTER 3
SYNTHESIS OF NON-PEPTIDE NPFF LIGANDS
Early on in our structure-activity relationship studies, the 4-anilindopiperidine scaffold
was determined to provide a chemically accessible scaffold as well as have three clear regions
from which to explore various modifications and structural alterations. Figure 15 describes
these regions as the aniline (region A), the nitrile which was transformed into a guanidine (region
B), and the piperidine nitrogen (region C). Each region offered an opportunity to investigate
which modifications may help or hinder our goal of improving binding affinity and selectivity
between NPFF1 and NPFF2receptors. Initially, the aniline moiety was removed; this provided an
analog with 10 µM affinity at NPFF1 receptor and 3372 nM at NPFF2. Likewise changing from
a secondary amine to an amide gave 1525 nM affinity at NPFF1 and 4034 nM affinity at
NPFF2. After the time of the work described below, other changes were made to the aniline
moiety of our scaffold. Substitutions off the aromatic ring included electron withdrawing groups
such as halogens (F or Cl) as well as electron donating groups such as (methoxy), for mono- or
di-substituted rings the meta position was favored over thepara position. For instance dichloroaniline substitution yielded an analog with 191 nM at NPFF1 and 409 nM at
NPFF2. While mono-substituted para-fluroaniline, gave 447 nM at NPFF1 and 1116 nM at
NPFF2. Similarly, the di-methoxy substituted aniline (with both substitutions at
the metapositions) gave a compound with 114 nM at NPFF1 and 987 nM at NPFF2.
Changing the substitution from aniline to a larger naphthyl and amino-naphthyl substituted
scaffold proved interesting. Switching to the amino-naphthyl substituted scaffold gave 94 nM at
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NPFF1 and 309 nM at NPFF2 while removing the nitrogen and substituting with a naphthyl
group gave binding affinities of 112 nM at NPFF1 and 30 nM at NPFF2. The removal of the
nitrogen effectively reversed affinity between NPFF1 and NPFF2.

The next region we explored was the guanidine region including the linkage between the
guanidine moiety and the piperidine ring. Changes in the linker length between the guanidine
portion and the piperidine portion were varied from 1 carbon to 5 carbons. The best compounds
had either a two-carbon glycine-type linkage or three-carbon arginine-type
linkage. Interestingly, switching from three carbons to two carbons also change from antagonist
to agonist. In order to explore the importance of the potential bi-dentate interaction afforded by
the guanidine certain modifications were made. First elimination of the primary amine either
through removal or alkylation leading to a secondary amine afforded compounds with affinities
of 1379 nM at NPFF1 and 5110 nM at NPFF2 and 1187 nM at NPFF1 and 4387 nM at
NPFF2 respectively. Bulkier substitutions off of the terminal amine did not improve
affinity. Likewise isosteric replacement of the imine with a carbonyl group did not improve
affinity giving 11780 nM at NPFF1and 17580 nM at NPFF2. In addition changing the primary
amine to a sulfur group did not improve affinity over the original guanidine structure. Moreover
simply giving a compound a permanent charge also gave affinities greater than the limits of the
assay at both NPFF1 and NPFF2. In fact the only change to the guanidine structure that was
tolerated was to create an imide-amine structure, this gave similar affinity to the guanidine
structure (imine-amine: 330.2 nM at NPFF1 and 1263 nM at NPFF2; guanidine: 477.9 nM at
NPFF1 and 1677 nM at NPFF2).
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Finally previous work in our lab explored the importance of the piperidine nitrogen. For
example replacing the nitrogen atom with a double bond gave a compound with affinities in the
thousand nanomolar range. Likewise moving the nitrogen atomfrom the four-position to the
three-position gave affinities of 904 nM at NPFF1 and 1893 nM at NPFF2. In addition early
work on substitutions off the nitrogen established that substitutions such as a methyl group or
ethyl benzyl group caused a poor of affinity for NPFF1 and NPFF2 receptors. Other substitutions
did not cause a complete loss of affinity but also did not improve affinity from our lead
compound. Therefore choosing substitutions that explored the chemical space surround the
piperidine nitrogen that had a greater bulk than a methyl group and some degree of planarity as a
biphenyl substitution lessened affinity was an important step in exploring the structure-activity
relationship of our lead structure.

Consequently, aliphatic substitutions such as cyclopropane, cyclopentane, and
cycloheptane were chosen to explore if an aromatic substitution was necessary. Likewise,
choosing pyridine substitutions offered the opportunity to explore the isosteric replacement of a
carbon with nitrogen in order to compare its affects to the benzyl derivative. Moreover at the
start of the project the napthyl derivative was the best lead compound, suggesting a larger planer
structure was tolerated at the binding site in the receptors. To further validate this hypothesis
quinoline and indole derivatives were purposed. Each of the purposed derivatives would be able
to be synthesized through a common synthetic intermediate. This common intermediate could
then be transformed through established synthetic procedures to final compounds.
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Synthesis of tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9oxa-2,5,7-triazaundecan-6-ylidenecarbamate, the common intermediate, began with
commercially available 1-benzylpiperidin-4-one under Strecker-like conditions 47-49 to afford in
68% yield 1-benzyl-4-(phenylamino)piperidine-4-carbonitrile (55). 1-benzyl-4(phenylamino)piperidine-4-carbonitrile (55) was then subjected to hydrogenation 50 using Raney
Nickel as the catalyst. Under these hydrogenation conditions the nitrile was selectively reduced
to a primary amine in 97 % yield while no side reactions such as debenzylation of the piperidine
nitrogen occurred. 4-(aminomethyl)-1-benzyl-N-phenylpiperidin-4-amine (56) underwent
peptide coupling procedure51, 52 affording in 72% yield tert-butyl (2-(((1-benzyl-4(phenylamino)piperidin-4-yl)methyl)amino)-2-oxoethyl)carbamate (57)-- the BOC-group
protected glycine derivative. Next BOC-group deprotection53 utilizing trifluoroacetic acid
results in near quantitative yield of the free amine 2-amino-N-((1-benzyl-4(phenylamino)piperidin-4-yl)methyl)acetamide (58). Finally addition of the BOC-protected
guanidine substitution is completed using a thiol derivative and base to yield tert-butyl 1-(1benzyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7-triazaundecan-6ylidenecarbamate (59)54 in 62% yield (Scheme 1).

28

Scheme 1 General Synthetic Scheme for key intermediate

Reagents and Conditions: a) Aniline, TMSCN, TEA, CH2Cl2; b) Raney Nickel, H2 (gas),
CH3OH; c) HOBt, EDCI, BOC-Gly-OH, TEA, CH2Cl2; d) TFA, CH2Cl2; e) 1,3-bis(tertbutoxycarbonyl)-2-methyl-2-thiopseudourea, TEA, DMF.

Scheme 2 offers an alternative route to the diversification by introducing the piperidine
nitrogen substitution prior to addition of the guanidine substitution. However, this method was
not utilized in the synthesis of the final compounds.
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Scheme 2 Alternative synthetic route to diversification

Reagents and Conditions: a) Aniline, TMSCN, TEA, CH2Cl2; b) Raney Nickel, H2 (gas),
CH3OH; c) HOBt, EDCI, BOC-Gly-OH, TEA, CH2Cl2; d) Pd/C, H2 (gas), CH3OH sat NH3; e)
ROH or RX, potassium carbonate, DMF.

Scheme 3 shows the general reaction scheme for the synthesis beginning with tert-butyl
1-(1-benzyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7triazaundecan-6-ylidenecarbamate (59) proceeding to tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (63) via
hydrogenation55, 56 utilizing palladium on carbon as the catalyst. Diversification of the structures
through N-alkylation (64-72), and removal of protecting groups53 with trifluoroacetic acid
afforded final compounds 73-81.
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Scheme 3 General synthetic scheme for diversification of key intermediate to final
compounds

Reagents and Conditions: a) Pd/C, H2 (gas), CH3OH sat. NH3; b) ROH or RX, potassium
carbonate, DMF; c) TFA, CH2Cl2

Synthesis of N-((1-(cyclopropylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2guanidinoacetamide (73) was achieved from deprotection of tert-butyl 1-(cyclopropylmethyl-4(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7-triazaundecan-6ylidenecarbamate (64) (Scheme 4). tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (63) underwent Nalkylation with addition of bromomethylcyclopropane and base (DIPEA) at 80 ºC for 24 hours
and yielded tert-butyl 1-(cyclopropylmethyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8dioxo-9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (64)57, 58 in 33% yield. tert-Butyl 1(cyclopropylmethyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7triazaundecan-6-ylidenecarbamate (64) and TFA were stirred together for 4 hours to give N-((1(cyclopropylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide (73)53 in
97% yield.
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Scheme 4 Synthesis of N-((1-(cyclopropylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2guanidinoacetamide (73)

Reagents and Conditions: a) DIPEA, bromomethylcyclopropane, 80 ºC, ACN, 24 hours; b) TFA,
DCM
tert-Butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7triazaundecan-6-ylidenecarbamate (63), neopentyl bromide, and DIPEA were combined in
acetonitrile and left to stir at room temperature for 48 hours to yield59 tert-butyl 1-(neopentyl-4(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7-triazaundecan-6ylidenecarbamate (65) at 25% yield. tert-butyl 1-(neopentyl-4-(phenylamino)piperidin-4-yl)10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (65) was then
deprotected53 with trifluoroacetic acid in DCM set to stir for three hours to yield 2-guanidino-N((1-neopentyl-4-(phenylamino)piperidin-4-yl)methyl)acetamide (74) at 20% yield (Scheme 5).
Scheme 5 Synthesis of 2-guanidino-N-((1-neopentyl-4-(phenylamino)piperidin-4yl)methyl)acetamide (74)

Reagents and Conditions: a) neopentyl bromide, DIPEA, r.t., ACN, 48 hours; b) TFA, DCM, 3
hours.
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Synthesis of tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1-(phenylamino)-4(2H-1,2,3,4-trazol-5-ylmethyl)cyclohexyl]methyl}carbamoyl)methyl]amino})methyl]carbamate
(66) was achieved by the reaction of potassium carbonate, chloromethyltetrazole, tert-butyl
10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-triazaundecan-6ylidenecarbamate (63) and a catalytic amount of potassium iodide in acetonitrile with heating
(100 ºC)60 at 75% yield. Deprotection53 of tert-butyl N-[(1Z)-{[(tertbutoxy)carbonyl]imino}({[({[1-(phenylamino)-4-(2H-1,2,3,4-trazol-5ylmethyl)cyclohexyl]methyl}carbamoyl)methyl]amino})methyl]carbamate (66) with
trifluoroacetic acid resulted in 30% yield of N-((1-((1H-tetrazol-5-yl)methyl)-4(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide (75) (Scheme 6).
Scheme 6 Synthesis of N-((1-((1H-tetrazol-5-yl)methyl)-4-(phenylamino)piperidin-4yl)methyl)-2-guanidinoacetamide (75)

Reagents and Conditions: a) chloromethyltetrazole, potassium carbonate, potassium iodide,
ACN, 100 ºC to r.t., 39 hours; b) TFA, DCM, 4 hours.

tert-Butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(pyridin-4ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (67) was
synthesized by combining tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4yl)-9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (63), 4-bromomethylpyridine, and DIPEA in
DMF at room temperature and allowing it to stir for 19 hours61, 62 at 60% yield. Deprotection53
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of tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(pyridin-4ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (67)
was afforded by stirring tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4(phenylamino)-1-(pyridin-4-ylmethyl)piperidin-4yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (67) and TFA for 4 hours yielding 2guanidino-N-((4-(phenylamino)-1-(pyridin-4-ylmethyl)piperidin-4-yl)methyl)acetamide (76) at
90% yield (Scheme 7).
Scheme 7 Synthesis of 2-guanidino-N-((4-(phenylamino)-1-(pyridin-4-ylmethyl)piperidin-4yl)methyl)acetamide (76)

Reagents and Conditions: a) 4-bromomethylpyridine, DIPEA, r.t., DMF, 19 hours; b) TFA,
DCM, 4 hours.

tert-Butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7triazaundecan-6-ylidenecarbamate (63), 3-bromomethylpyriidine and Hünig’s base were
combined in DMF and left to stir for 45 hours63 resulting in 60% yield of tert-butyl N-[(1Z){[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(pyridin-3-ylmethyl)piperidin-4yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (68). Deprotection53 of the resulting
pale yellow solid (68) with TFA were stirred in DCM for 4 hours resulting in 90% yield of 2guanidino-N-((4-(phenylamino)-1-(pyridin-3-ylmethyl)piperidin-4-yl)methyl)acetamide (77)
(Scheme 8).
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Scheme 8 Synthesis of 2-guanidino-N-((4-(phenylamino)-1-(pyridin-3-ylmethyl)piperidin-4yl)methyl)acetamide (77)

Reagents and Conditions: a) 3-bromomethylpyridine, DIPEA, r.t., DMF, 45 hours; b) TFA,
DCM, 4 hours.
N-((1-(cycloheptylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide
(78) and N-((1-(cyclopentylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2guanidinoacetamide (79) both required the modification of the alkylating agent prior to the Nalkylation step. For N-((1-(cycloheptylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2guanidinoacetamide (78) the alkylating agent was cycloheptane methanol, in order to create a
better alkylating agent, the alcohol was converted to a mesylate 64. This conversion created a
better leaving group for the N-alkylation step (Scheme 9). In the case of N-((1(cyclopentylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide (79) in lieu
of creating a mesylate, a tosylate of the alcohol (cyclopentane methanol) was made (Scheme 10).
The change from mesylate to tosylate assisted in visualization of the product on TLC.
Scheme 9 Alkylating agent cycloheptylmethyl methanesulfonate (89)

Reagents and Conditions: a) methylsufonyl chloride, TEA, 0 ºC, ethyl acetate, 2 hours.
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Scheme 10 Synthesis of cyclopentylmethyl tosylate (92)

Reagents and Conditions: a) tosyl chloride, TEA, 0 ºC, ethyl acetate, 3.5 hours.
Once the alkylating agent was prepared (89 or 92), synthesis of the corresponding N-alkylated
analog occurred. 2,2-dimethylpropyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1(cycloheptylmethyl)-4-(phenylamino)piperidin-4yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (69) was synthesized64 by combing tertbutyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-triazaundecan-6ylidenecarbamate (63), cycloheptylmethyl methanesulfonate (89), along with potassium
carbonate and potassium iodide in acetonitrile at 70 ºC. The reaction stirred for 17 hours at 70
ºC and after cooling to room temperature was stirred for an additional 5 hours. Deprotection 53 of
2,2-dimethylpropyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1-(cycloheptylmethyl)-4(phenylamino)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (69) utilizing
TFA in DCM afforded N-((1-(cycloheptylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2guanidinoacetamide (78) (Scheme 11).
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Scheme 11 Synthesis of N-((1-(cycloheptylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)2-guanidinoacetamide (78)

Reagents and Conditions: a) cycloheptylmethyl methanesulfonate, K2CO3, KI, ACN, 70 ºC to
r.t., 22 hours; b) TFA, DCM, 5 hours.
With cyclopentylmethyl 4-methylbenzenesulfonate (92) in hand, addition of tert-butyl
10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7-triazaundecan-6ylidenecarbamate (63), potassium carbonate, and potassium iodide were set to stir in ACN at 70
ºC64. The reaction stirred at 70 ºC for 24 hours was then left to stir at room temperature for 18
hours with poor yield of 12% despite monitoring of the reaction via TLC. tert-butyl N-[(1Z){[(tert-butoxy)carbonyl]imino}({[({[1-(cyclopentylmethyl)-4(phenylamino)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (70)
underwent deprotection53 with TFA in chloroform resulting in N-((1-(cyclopentylmethyl)-4(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide (79) in 85% yield (Scheme 12).
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Scheme 12 Synthesis of N-((1-(cyclopentylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)2-guanidinoacetamide (79)

Reagents and Conditions: a) cyclopentylmethyl tosylate, K2CO3, KI, ACN, 70 ºC to r.t., 22
hours; 2) TFA, DCM, 4 hours.
Synthesis of tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1(quinolin-8-ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (71)
began by combining tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9oxa-2,5,7-triazaundecan-6-ylidenecarbamate (63), 8-bromomethylquinoline, and DIPEA in DMF
at room temperature65. The reaction stirred for 21 hours with 59% yield of desired product (71).
Deprotection of tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1(quinolin-8-ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (71)
using TFA in chloroform resulted in 90% yield of 2-guanidino-N-((4-(phenylamino)-1-(quinolin8-ylmethyl)piperidin-4-yl)methyl)acetamide (80) (Scheme 13).
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Scheme 13 Synthesis of 2-guanidino-N-((4-(phenylamino)-1-(quinolin-8-ylmethyl)piperidin4-yl)methyl)acetamide (80)

Reagents and Conditions: a) 8-bromomethyl quinoline, DIPEA, r.t., DMF, 21 hours; b) TFA
CHCl3, 4 hours.

In order to synthesize tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]amino}({[({[1-(1Hindol-6-ylmethyl)-4-nylamino)piperidin-4yl]methyl}carbamoyl)methyl]amino})methylidene]carbamate (72), (1H-indol-6-yl)methyl 4methylbenzenesulfonate (96) need to first be prepared. Preparation of (1H-indol-6-yl)methyl 4methylbenzenesulfonate (96) began first with reduction66 of commercially available 1H-indole-6
carboxylic acid at 91% yield (Scheme 14). Following the reduction the (1H-indole-6yl)
methanol (95) was then converted to a tosylate using 4-methylbenzene-1-sulfonyl chloride and
triethylamine in ethyl acetate resulting in 50% yield of (1H-indol-6-yl)methyl 4methylbenzenesulfonate (96) (Scheme 15) 64.
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Scheme 14 Synthesis of (1H-indol-6-yl)methanol (95)

Reagents and Conditions: a) LAH, THF, r.t. to 0 ºC, 25 hours.
Scheme 15 Synthesis of (1H-indol-6-yl)methyl 4-methylbenzenesulfonate (96)

Reagents and Conditions: a) tosyl chloride, TEA, ethyl acetate, 4 hours.

tert-Butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7triazaundecan-6-ylidenecarbamate (63), (1H-indol-6-yl)methyl 4-methylbenzenesulfonate (96),
potassium carbonate, and potassium iodide were combined in ACN and left to stir for 48 hours at
70 ºC and then allowed to cool to room temperature where the reaction continued to stir for an
additional 17 hours64. This resulted in 14% yield of tert-butyl N-[(1Z)-{[(tertbutoxy)carbonyl]amino}({[({[1-(1H-indol-6-ylmethyl)-4-nylamino)piperidin-4yl]methyl}carbamoyl)methyl]amino})methylidene]carbamate (72). Deprotection53 of tert-butyl
N-[(1Z)-{[(tert-butoxy)carbonyl]amino}({[({[1-(1H-indol-6-ylmethyl)-4-nylamino)piperidin-4yl]methyl}carbamoyl)methyl]amino})methylidene]carbamate (72) using TFA in chloroform
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resulted in 53% yield of N-((1-((1H-indol-6-yl)methyl)-4-(phenylamino)piperidin-4-yl)methyl)2-guanidinoacetamide (81) (Scheme 16). Final compounds purity and compositions were
verified through various analytical methods including NMR, HPLC, and MS.

Scheme 16 Synthesis of N-((1-((1H-indol-6-yl)methyl)-4-(phenylamino)piperidin-4yl)methyl)-2-guanidinoacetamide (81)

Reagents and Conditions: a) K2CO3, KI, 70 ºC to r.t., ACN, 65 hours; b) TFA, CHCl 3, 4 hours.

IN VITRO EVALUATION AND RESULTS
In order to create the most viable leads, in vitro evaluation was conducted in two stages.
The first stage consisted of a receptor binding assay. The receptor binding assay was performed
by our collaborators at the Institut de Pharmacologie et Biologie Structurale, CNRS in Toulouse,
France. The affinities of ligands on NPFF1 and NPFF2 receptors were evaluated by competition
experiments using the selective NPFF1 and NPFF2 radioligands [3H]-NPVF and [3H]-EYF,
respectively, in membranes of CHO cells stably expressing each receptor67, 68. The non-specific
binding was determined in the presence of 1 µM YVPNLPQRFa (for hNPFF1 receptor) and 1
µM EYWSLAAPQRFa (for hNPFF2 receptor). For membrane preparation, CHO cells
expressing human NPFF receptors were harvested in phosphate buffer saline (PBS), frozen at
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least for 1 h at -70°C, and then homogenized in 50 mM Tris-HCl, pH 7.4 in a Potter Elvehjem
tissue grinder. The nuclear pellet was discarded by centrifugation at 1,000 g for 15 min at 4°C,
and the membrane fraction was collected upon centrifugation of the supernatant at 100,000 g for
30 min at 4°C. Membranes were aliquoted and stored at –80°C in Tris 50 mM, pH 7.4 and the
protein concentration was determined by the Lowry method. Binding of [3H]-NPVF and [3H]EYF was measured by rapid filtration. Membranes (5-15 µg protein) were incubated in
polypropylene tubes in a final volume of 500 µl containing 50 mM Tris-HCl, pH 7.4, 0.1%
bovine serum albumin, 60 mM NaCl (for NPFF2 receptors only), the radioligand at 0.5-1 nM
and compounds to be tested at the desired concentration. After 1 h incubation at 25°C, samples
were rapidly filtered on Whatman GF/B filters preincubated in 0.3% polyethylenimine. The
filters were rinsed three times with 4 ml of ice cold buffer containing 0.1 % bovine serum
albumin, and the bound radioactivity was counted in a liquid scintillation spectrophotometric
counter (50 % efficiency, Packard). [3H]-NPVF and [3H]-EYF were custom-made by RC
TRITEC AG (Teufen, Switzerland) by hydrogenation of the unsaturated peptide precursors with
99% tritium gas. Tritiated products were purified (> 98%) by HPLC and dissolved in ethanol to
obtain 1 mCi/ml (37 MBq/ml). To further test the molecule in a functional assay binding
affinities must be less than 300 nM. In the case of the compounds described in this work none
showed binding affinities less than 300 nM and were therefor not screened in a functional assay.
Figure 23 describes the binding data for some of the relevant synthesized compounds including
those described above.
The newly synthesized compounds help further elaborate certain trends established in our
current understanding of the receptor binding space and differences between NPFF1 and NPFF2
receptors. For instance, previously synthesized compounds showed that a lack of substitution of
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the piperidine nitrogen or a simple methyl substitution do not afford strong binding affinities at
either subtype of receptor. Moving from a benzyl substitution pattern to a cyclopropyl
substitution maintains the preference for NPFF1 receptor subtype. Interestingly increasing the
cyclic aliphatic substitution from a cyclopropyl to a cyclopentyl or cyclohexyl reverses the
preference from NPFF1 receptor subtype to NPFF2 receptor subtype. While in the patent
literature30 increases in aliphatic ring size have improved affinity this was not the case for our
small molecule. Using an isosteric replacement of nitrogen for carbon in the benzene ring
substitution we anticipated creating a novel chemical space with similar affinity to the current
lead compounds. Yet when tested binding affinities for these molecules were less than the
benzyl substituted compound and were not further pursued in the functional assays. However,
when comparing the isosteric replacement of nitrogen for carbon in our larger planar
substitutions (naphthalene to quinoline) the relative affinity for each subtype was reversed. In
other words, the naphthalene substituted compound (53, MES305) showed preference for NPFF2
receptor subtype (129 nM at NPFF2; 538 nM NPFF1); while the quinoline substituted compound
(80, JVM32) showed preference for NPFF1 receptor subtype (580 nM NPFF1; 1080 nM NPPF2).
The reasoning behind this reversal may be tied to the 3-D structure of the binding pocket of each
subtype as well as the relevant amino acids within said binding pocket; since no crystal structure
of the receptor exists to date this is still theory.
Overall, binding data provides a first look at the potential benefits or detriments of
changes in substitutions of the lead compound. For the newly synthesized compounds described
the binding data provides a guide to further lead development and offers potential trends to direct
selectivity between receptor subtypes.
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Figure 23 Synthetic Non-Peptide Ligands Binding Data

NT= not tested; data based on displacement of [3H]-NPVF and [3H]-EYF for NPFF1 receptors
and NPFF2 receptors, respectively.
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CHAPTER 4
IN VIVO MODELS OF PAIN
While in vitro work is a valuable asset to the medicinal chemist, it cannot accurately
describe what happens in a dynamic living system. Although arguments can be made on both
sides for the relevancy, validity, and justification of animal models, to date no viable alternatives
exist. Animal models remain relevant because they offer a controlled environment to model
human behaviors. Pain requires a wide range of animal models in order to best demonstrate
clinical relevance. First a point of clarification, pain is a subjective term and is defined as an
unpleasant sensory and emotional experience associated with actual or potential tissue damage 69,
70

. Therefore a more accurate term to use in regards to animal models is nociception which is

defined as the neural processes of encoding and processing noxious stimuli69, 70. An ideal
animal model of nociceptive behavior has the following characteristics 34:


Specific—the stimulus causes the nociceptive response and may be distinguished from
non-nociceptive causing stimulus



Sensitive—the stimulus causes a quantifiable response that correlates to the intensity of
the response



Valid—the model must differentiate between behavioral changes triggered by the
nociceptive stimulus and those that may be triggered by other stimuli (e.g. a
pharmacological agent)
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Reliable—the model must be consistent in results obtained when animals are retested
with an identical or equivalent test



Reproducible—the results of a test must repeatable within a single laboratory and
between laboratories.

Though no animal model matches this ideal completely a variety of models exist that do offer
relevant options for basic research in nociception and pain.
Thermal, electrical, mechanical, or chemical stimuli can be used to test nociception34.
Thermal nociceptive tests include tail-flick, hot plate, paw withdrawal. The tail-flick test has
two varieties; the first uses radiant heat to a small area of the tail of the animal, the second uses
predetermined temperature water and immerses the tail. Though each of these tests measures the
time until the animal withdrawals its tail from the stimulus, the area of the tail affected is quite
different. In the case of the radiant heat only a very small area of the tail is exposed to the heat
source and depending on intensity of the heat the reaction time can vary34. For the heated water
a greater surface area of the tail is exposed to the stimulus and can therefore possibly creating a
shorter reaction time34. Another thermal nociceptive test is paw withdrawal 34 or Hargreaves
method69, 71. In this test heat is applied to a paw instead of the tail; it holds two advantages, first,
it does not involve the tail—the main temperature-regulating organ of the rodent34; second, use
of the contralateral paw can be used as a control 69. A final thermal nociception test is the hot
plate test. For the hot plate test, the animal is placed in a cylindrical container on a heated
ceramic plate (set temperature such as 52ºC) and the time until either a paw licking or jumping
response occurs is measured34. Cold variations of tail-flick and hot plate do exist but are use
much less frequently34, 69.
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Mechanical tests of nociception usually involve the hind paw of the rodent being tested.
In one example the hind paw is pinned between a flat surface and a blunt point which can
increase the pressure applied to the paw in a controlled manner. The measure of nociception is
based on the level of pressure prior to the predetermined behavioral reaction (i.e. withdrawal of
paw or vocalization)34. A variation of this test known as Randall-Selitto method72, involves
inflaming the paw that is tested and comparing it to a healthy paw. The method increased
sensitivity compared to the original test and by using a non-steroidal anti-inflammatory drug
(NSAID) as well as comparing a healthy and inflamed paw of the same rodent the two major
pitfalls can be overcome34. The von Frey nociception test involves filaments of a set length and
varying in diameters set on applicators69. These filaments are calibrated to a certain pressure and
are applied to the plantar surface of the paw of the rodent and withdrawal of the paw is the
anticipated response69. Automated apparatus exist to help create a continuous scale of
stimulation69.
In addition to mechanical and thermal stimulation certain nociceptive models use
electrical stimulation. Electrical stimulation offers a non-specific response that does not have a
direct link to nociception. Different levels of electrical stimulation are used and most often the
measure of threshold is based on flinching/movement or escape, vocalization and biting of
electrodes34. While electrical stimulation usefulness stems from the variety of behaviors that
may be measured and its non-invasive nature overall it is no longer popular34.
Chemical stimuli offer an important variation that differs from thermal, mechanical, or
electrical stimuli. Chemical stimulation often most closely resembles clinical pain 34 due to its
ability to produce distinct behaviors that are not measured at a threshold but instead are
quantified by time engaged in the specific behavior. Chemical stimulation models tonic pain and
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involve intradermal or intraperitoneal injections34, 69. The two most common examples of
chemical stimulation are the writhing test and the formalin test. The writhing test begins with an
intraperitoneal injection in the mouse or rat. The algesiogenic agent traditionally used is
phenylbenzoquinone yet many modifications have been made to the agent injected including
concentration, temperature, and volume as well as the exact agent used 34. Some of the behaviors
observed are abdominal contractions, twisting of abdominal muscles, and a lessening of motor
activity34. These behaviors are measured as an occurrence per unit of time 34. Whereas the
writhing test is not very specific in that other non-analgesic agents may alter the observed
behaviors, it does offer a degree of sensitivity that other tests may not.
Chemical, electrical, mechanical, and thermal stimuli offer variety and reproducible
results for short duration models of pain. Although chemical stimulation can depict a longer
duration of pain it still does not offer the same clinical relevance for describing chronic pain. In
order to model chronic pain such as neuropathic pain more complex and involved models are
used.
For example drug induced neuropathic pain models attempt to recreate the chronic pain
that can arise from cancer chemotherapy treatments. Certain natural product derived
chemotherapeutic agents are known to cause pain in the peripheral nerves. Animal model of
vincristine (a vinca alkaloid from the periwinkle plant) neuropathic pain demonstrates a dosedependent mechanical allodynia as well as sensitivity towards changes in temperatures 73, 74. In
addition to vincristine, paclitaxel derived from Pacific yew trees can also cause a state of chronic
pain with repeated exposure such as chemotherapy treatment. In the case of paclitaxel, animal
models again demonstrate similar results to human clinical experiences by producing allodynia
and thermal hyperalgesia73, 74. The rate and quantity of dosing can affect the severity of the pain
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produced in the animal model and high versus low dose models each have merits depending on
which symptoms wish to be studied. Another chemotherapeutic agent that causes neuropathic
pain in patients is cisplatin73, 74. This agent interferes with DNA which may be part of the cause
of the neuropathy73. Cisplatin also causes nephrotoxicity which can complicate the creation of a
complete animal model due to systemic toxicity occurring prior to the neurotoxicity74. These
difficulties have been overcome by adjusting the dosage and schedule of dosing in the animal
models74.
Animal models of drug-induced neuropathic pain are just one example of chronic pain
models. Clinical examples of chronic pain may stem from a preexisting condition or disease; as
such animal models have been developed to mimic the diseases including the chronic pain that
may be associated with the disease. For instance, diabetes can induce peripheral neuropathy, in
one animal model of this pain the animal is injected with streptozocin (STZ) and alloxan 74.
These toxins target β-cells of the pancrease74. Though this is the most common model for
studying peripheral diabetic neuropathy it differs in that it can cause severe distress to the animal
and kill other cells other than the beta cells which may confuse interpretation of the results73.
Genetic models of diabetes are available which to varying degrees can develop peripheral
diabetic neuropathy74. Post-herpetic neuralgia caused by the herpes-zoster virus affects the
dorsal root ganglia73. In order to replicate the pain triggered by the latent viral infection animal
models have attempted to infect the animal with virus73, 74. Within the last decade a non-viral
model using a potent TRPV1 agonist (resiniferotoxin) which diminishes capsaicin sensitive
afferents thereby reproducing the mechanical and thermal sensitivities in rats74, 75. Models for
pain caused by HIV or cancer such as bone cancer exist 73, 74.
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Central pain models are based on spinal cord injuries in humans. Four main models
exist, first, weight drop or contusive model, second, photochemical spinal cord injury, third,
excitotoxic spinal cord injury, and fourth, spinal hemi-section model. In weight drop or
contusive model, the spinal cord is exposed and a weight is dropped down a tube to direct the
drop. The resulting injury causes a compressed spine as well as physical damage to the cord 73, 74.
The damage causes motor and sensory dysfunction and leads to tactile allodynia73, 74. For the
photochemical spinal cord injury model, a dye (erythrosine B) is injected into the spinal cord.
The cord is then exposed to argon ion laser which excites the dye causing blood vessel stasis and
ischemia within the microvasculature of the spinal cord 73, 74. In the excitotoxic spinal cord
injury model, an intraspinal injection of quisqualic acid or other excitatory amino acid causes
spontaneous pain and mechanical allodynia 73, 74. This model demonstrates central mechanisms
and neuronal substrates responsible for onset and progression of altered sensory states post spinal
cord injury73, 74. Finally the spinal hemi-section spinal cord injury model mimics BrownSequard Syndrome in humans74. This model involves a longitudinal incision that exposes
several segments of the spinal cord74. It is advantageous compared to some of the other models
because the number and types of injured fibers can be controlled 74. Moreover, there is a
separation of the injured and non-injured environments74.
In addition to central pain models, peripheral nerve injury models also allow for
exploration of cause and effect of various injuries. While a variety of models exist, a few are
more common. Beginning with the complete sciatic nerve transection or neuroma model where
a section of the sciatic nerve is removed resulting in formation of a lesion or neuroma (tumor
composed of nerves growing in all directions)73, 74. This model represents phantom limb pain in
humans with the exception that in humans generally no nerve lesion exists 73, 74. The behaviors
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observed in the animal model include autotomy or self-attack and mutilation of denervated
limb73, 74. Chronic constriction injury model starts with exposure of the sciatic nerve then three
to four loose ligatures are tied around the nerve 74. Constriction of the sciatic nerve is associated
with intraneural edema, focal ischemia, and Wallerian degeneration 74. These lead to behavioral
manifestations of spontaneous pain like licking, limping and mild to moderate autotomy74. The
chronic constriction model is used in research for spontaneous pain and abnormal sensation 74.
The Seltzer model76 or partial sciatic nerve injury involves exposure of the sciatic nerve with a
tight ligation on 1/3 to ½ of common sciatic nerve diameter 74.
Partial sciatic nerve injury mimics the neuropathic pain seen in humans74 suffering from
causalgia77—a constant usually burning pain that results from injury to a peripheral nerve and is
often considered a type of complex regional pain syndrome. This animal model is useful
because it has a characteristic immediate onset and long-lasting continuation of touch evoked
allodynia and hyperalgesia74. Another model of causalgia is the spinal nerve ligation. This
model differs from chronic constriction injury and partial sciatic nerve injury in that it induces
more extensive and relevant damage; likewise, spinal nerve ligation has an advantage that
injured and intact segments are seperate73. In spinal nerve ligation, behavioral changes like
mechanical and cold allodynia, thermal hyperalgesia develop within one to two days of the
surgery and continue for ten to sixteen weeks74.
In the spared nerve injury model the sciatic nerve along with its three terminal branches
are exposed. Two of the branches are tightly ligated while the third is left alone 74. This model
differs from those previously described in it allows for comparison of mechanical and thermal
stimuli of non-injured areas next to the injured area thereby allowing for further elucidation of
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the affects unharmed nerves have in relation to the injured nerves74. Figure 24 offers a
visualization of some of the peripheral nerve models74.
In the end, whether an animal model induces a state of pain through a thermal,
mechanical, or chemical stimulus is short- or long-tern the validity of the model stems from the
information generated. If the model can effectively translate human pain symptoms and
conditions then it can offer a reasonable option for researchers in the quest for understanding and
discovery.
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Figure 24 Peripheral Nerve Models

Various peripheral nerve injury models: 1) spinal nerve ligation; 2) chronic constriction injury
using four ligatures; 3) ligation of common peroneal nerve; 4) neuroma model (complete sciatic
nerve transection); 5) partial sciatic nerve ligation; 6) spared nerve injury tibial and sural model;
7) spared nerve injury peroneal and tibial nerve model. Reproduced with permission from [80].
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CHAPTER 5
FORMALIN ASSAY: EFFECTS OF CONCENTRATION

As mentioned an effective animal model of nociception is specific, sensitive, valid,
reliable, and reproducible34. The formalin assay meets these criteria and offers an opportunity to
explore the connection between nociception and the neuropeptide FF system in the treatment of
pain. Since its isolation from bovine brain in 19851, NPFF has been linked to the opioid system
and its potential role in treatment of pain. In more recent works, the neuropeptide FF system has
been linked to inflammatory and neuropathic pain2, 78-80. Likewise the anatomical distribution of
NPFF receptors in the brain and spinal cord also suggest that the neuropeptide FF system may be
involved in control of nociception6, 8. Together these factors suggest further study of selective
neuropeptide FF ligands in the formalin assay may further define the role the NPFF system plays
in pain management.
Initially describe in 1977 by Dubuisson and Dennis, the formalin assay offers an effective
model of tonic pain81. An intraplantar injection to the hind paw of formalin, a dilute solution of
formaldehyde, causes a biphasic pain response81. The two phases can act as a screen for
analgesics with the early phase responding to centrally acting analgesics while the late phase
responds to peripheral82. Originally an arbitrary scale was established to score behaviors related
to the manifestation of pain81, later works82-85 began to use time engaged in characteristic
behaviors defined as licking, biting, or favoring of injected paw. Varying concentrations of
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formalin have been reported to produce the characteristic two phase response of the formalin
assay84. The purpose of this work was to determine the lowest concentration that demonstrated
the biphasic pain response at a given dose of morphine. The behaviors measured were licking or
biting, of injected paw with measurement of locomotor activity as a secondary measure.
Various concentrations of formalin are reported82, 84, 86-88 to produce the characteristic
biphasic response of the formalin assay, in order to determine which concentration would
produce the best response at a given morphine dose (5 mg/kg) four concentrations (0.1%, 0.2%,
1%, 5%) were tested. A control of saline pretreatment (1mg/kg, i.p.) followed 15 minutes later
with a 10 µL of saline (intraplantar) was established. Likewise a second negative control of
pretreatment with morphine (5 mg/kg, i.p.) followed by 10 µL saline (intraplantar) verified that
the neither intraplantar nor intraperitoneal injections would affect the outcomes for the formalin
injections (Figure 25).
A formalin concentration of 0.2% did not show significance versus saline at any time
point throughout the experiment (Figure 26). 0.1% formalin concentration showed significance
(p< 0.01) at the 15 minute time point compared to saline (Figure 27). While 1% formalin
concentration showed significance (p< 0.5) at the 5 minute time point (Figure 28). Finally 5%
formalin concentration showed significance (p< 0.01) at the 5 minute and 40 minute time points,
while at the 55 minute time point significance was less (p< 0.5) and at the 60 minute time point
significance was greatest (p< 0.001) (Figure 29). In addition to the representative pain
behaviors of licking or biting of injected paw, locomotor activity was also monitored. It was
found that neither the saline nor formalin intraplantar injection at any concentration significantly
diminished or increased locomotion relative to saline (Figure 30).
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Figure 25 Controls for Formalin Assay

15 minute pretreatment with 1 mg/kg saline or 5 mg/kg i.p. morphine; 10 µL intraplantar
injection of saline, * p< 0.5.
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Figure 26 Formalin Concentration of 0.2%

15 minute pretreatment with morphine (5 mg/kg, i.p.) followed by 10 µL saline or 0.2% formalin
intraplantar injection.
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Figure 27 Formalin Concentration of 0.1%

15 minute pretreatment with morphine (5 mg/kg, i.p.) or saline (1 mg/kg, i.p.) then 10 µL saline
or 0.1% formalin intraplantar injection, * p< 0.5, ** p< 0.01.
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Figure 28 Formalin Concentration of 1%

15 minute pretreatment with saline (1 mg/kg, i.p.) or morphine (5 mg/kg, i.p.) then 10 µL saline
or 1% formalin intraplantar injection, * p< 0.5.
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Figure 29 Formalin Concentration of 5%

15 minute pretreatment with saline (1 mg/kg, i.p.) or morphine (5 mg/kg, i.p.) followed by 10 µL
intraplantar injection of 5% formalin, * p< 0.5, ** p< 0.01, *** p<0.001.
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Figure 30 Locomotor Activity for Formalin Assay

No statistically significant difference between saline and formalin concentrations.

The data obtained are in agreement with several reports in the literature81-91. For instance
while 20 or 25 µL is used as the volume for intraplantar injection of formalin in mice 82, 83, 85 and
50 µL for rats81, 88, 10 µL injection volume has been used in mice in the orofacial version of the
formalin assay where the injection site is located on the face of the animal as opposed to the
paw86, 87, 90. In this work, 10 µL formalin injections into the paw still produced the expected
biphasic response. Moreover based on work by Bornhof86, Rosland84 and Sufka85 a morphine
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dose of 5 mg/kg was chosen because it produced statically significant pain relief and still showed
the desired biphasic response. Similarly effect of formalin concentration has also been
explored84-87. Again the present work also demonstrates that though low concentrations of
formalin (0.1%, 0.2%, 1%) do produce both an early and late phase of manifestations of pain (i.e.
licking or biting of injected paw), the statistical significance is not as strong compared to 5%
formalin concentration.
Overall the formalin assay provides a tonic model of pain that differs in both duration and
type of stimulus from the hot plate and tail-flick assays the other traditional methods for testing
of analgesics. For the work presented 5% concentration of formalin offers the best opportunity
to observe the biphasic response with a pretreatment of morphine (5 mg/kg, i.p.). Like
previously reported82-88, 90, 91 each concentration demonstrated the expected two phases however
only the 5% concentration showed multiple time points as having statistical significance. By
only measuring the time spent engaging in pain behaviors of licking or biting of the injected paw
numbers are lower (but reliable) than others reported in the literature 82, 84, 85. The present work
confirms what is represented in the literature81-91 with the addition of a smaller intraplantar
injection volume can still produce the desired characteristics of the formalin assay.
In terms of NPFF ligands, selectivity and the exact pharmacology of NPFF are still
pertinent issues that need to be resolved. NPFF has been demonstrated to cause both antinociceptive as well as pro-nociceptive properties9. Interestingly in models of inflammation such
as Complete Freud’s Adjuvant model NPFF has an anti-allodynia affect78. While the formalin
assay is a less formal model of inflammation, it may prove interesting to see if selective NPFF
ligands can reduce the late phase of the formalin assay. For instance early work on a selective
NPFF2 ligand does in fact show a statistically significant decrease in licking/biting in a rat model
62

of the formalin assay9. Likewise, recent work92 suggests that the late phase of the formalin assay
may be spinally modulated therefore intrathecal administration of NPFF or selective NPFF2
ligands may offer greater insight into these claims.
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CHAPTER 6
CONCLUSIONS AND FUTURE DIRECTIONS

For over 25 years research on neuropeptide FF has defined and redefined the role of this
RF-amide peptide. Early work focused on defining with which receptors neuropeptide
interacted4 as well as determining which amino acids within the peptide were critical for affinity
and activity17. Pharmacological studies began to further develop the roll of NPFF from antiopioid activity1 to temperature regulation15 to effects on food intake13. With nearly a decade of
research already complete the role of NPFF had clear links to pain modulation 12, 78, 93 and
development began to move towards creating selective ligands 5, 21, 44 for the two NPFF receptor
subtypes (NPFF1 and NPFF2). While peptide work27 continued in the next decade of NPFF
research, small molecules selective for NPFF1 or NPFF2 receptors began to appear in the patent
literature30, 32, 35, 36, 38, 39, 66. Often these molecules contained a heterocycle and a guanidine
moiety. While some groups focused on creating selective NPFF2 receptor ligands29, 31, others
worked towards NPFF1 selectivity35, 36. Although a diverse range of substitutions from
aliphatic30 to multiple heterocycles29 to hydrazines31 can offer selective non-peptide ligands no
clearer SAR than a heterocycle and a guanidine moiety can be drawn.
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To begin the 4-anilidopiperdine core as its features aligned well with the C-terminal
features of endogenous neuropeptide FF. Moreover this core offered a synthetically viable
starting point for a systematic exploration of structural changes affecting affinity toward NPFF
receptors. Changes to the substitution pattern around the aniline portion of the core structure did
not create selective ligands; however, it did create ligands with affinity in the low micromolar
range. Replacement of the aniline with a naphthalene-1-amine showed weak binding for NPFF2
and no displacement of radioligand at NPFF1. Loss of the aniline nitrogen in other modifications
did not enhance binding affinity but did switch relative selectivity. Further refinement around
the core structure lead to similar types of findings such as moving from an arginine linker to a
glycine linker between the core and the guanidine moiety switched the ligands from antagonists
to agonists.

Early work on the substitutions off the piperidine nitrogen suggested that small

substitutions such as methyl did not enhance binding or selectivity but larger substitutions such
as naphthalene did improve affinity though not selectivity.
To better determine the effects of the substitution off the piperidine nitrogen various
aliphatic and aromatic substitutions were made. Isosterically replacing one of the benzyl carbons
to nitrogen creating pyridine analogs did not improve selectivity or affinity to the NPFF receptor
subtypes. Similarly changing from naphthalene to a quinoline substitution did not improve
affinity but did give a ten-fold selectivity for NPFF1 over NPFF2 receptors. Substituting an
indole in place of the benzyl gave weak affinity for NPFF2 and did not displace the radioligand at
NPFF1. Switching from aromatic substitutions to aliphatic substitutions overall did not improve
selectivity or affinity. Bulky aliphatic substitutions such as a cycloheptyl ring did not bind
within the limits of the assay perhaps because of the lipophilicity of such a molecule. However,
smaller aliphatic substitutions such as cyclopentyl ring and cyclopropyl ring did displace
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radioligand though again with very weak affinity and minimal selectivity. In the end none of the
newly synthesized piperidine nitrogen modifications enhance the lead template design.
In addition to synthesis, in vivo pharmacological evaluation is a critical component of
drug discovery and design. Described in the beginning as an anti-opioid system, the role of
NPFF has continued to expand through pharmacological evaluation. In order to best understand
NPFF and intern the non-peptide small molecules designed to interact with the NPFF system the
right pharmacological tools are necessary. When testing for analgesic effects two main assays
are used—tail-flick and hot plate. These assays are well established and describe peripherally or
centrally mediated responses respectively. Although these assays are useful, both only measure
acute pain. In order to determine if more long term pain relief is possible a model of tonic pain
is beneficial. The formalin assay offers this model of tonic pain. It provides a means to
distinguish if the analgesic effects are centrally or peripherally located based on which of the two
phases are affected. Moreover, various established classes of drugs have proven effects on the
different phases (early or late) of the assay. This allows for competing experiments to help
evaluate the effectiveness of the test compound.
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In the future modifications of the guanidine moiety may provide the best opportunity for
a clinically relevant lead compound. At present most of these types of modifications has not
improved affinity or selectivity; therefore, it may require a deeper look into formulation and
potentially linking one active compound to a molecule or compound that can undergo active
transport. Likewise similar molecules have been explored for their interactions with calcium
channels94 consequently it is important to be aware of non-NPFF targets and affects these
compounds may have. Furthermore advances in the pharmacological role of NPFF allow for
opportunities to look at its potential in combating inflammation as well as its anti-opioid
properties. In the end as the role of NPFF continues to develop and expand the need for selective
non-peptide small molecules remains a pertinent challenge.
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GENERAL EXPERIMENTAL
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Chemistry
Reagents and starting materials were obtained from commercial suppliers (SigmaAldrich, Milwaukee, WI) and were used without puriﬁcation. Pre-coated silica gel GF Uniplates
from Analtech were used for thin-layer chromatography (TLC). Column chromatography was
performed on silica gel 60 (Sorbent Technologies). 1H and 13C NMR spectra were obtained on a
Bruker APX400 at 400 and 100 MHz, respectively. The mass spectra (MS) were recorded on
Waters Acquity Ultra Performance LC with ZQ detector in ESI mode. Chemical names were
generated using ChemDraw Ultra (CambridgeSoft, version 12.0).

1-benzyl-4-(phenylamino)piperidine-4-carbonitrile (55)
1-benzylpiperidin-4-one (34.3 mmol) was added to glacial acetic acid and stirred for 10 minutes.
Then aniline (37.75 mmol, 1.1 equivalents) was added drop wise to the mixture and left to stir
for 25 minutes at 0 ºC. Then the reaction mixture was brought to room temperature and left to
stir for 5 minutes. After 30 minutes trimethylsilyl cyanide (37.75 mmol, 1.1 equiv) was added
drop wise. The reaction was left to stir for six hours and then stopped with the addition of
aqueous sodium hydroxide to approximately pH of 10. The solution was extracted three times
with methylene chloride and the organic layers were dried over sodium sulfate. The organic
layers were then evaporated to solid. Purification through re-crystallization with acetonitrile,
refluxing for three hours then cool to room temperature and stand overnight in freezer, resulted
in a fine white solid. Yield: 68%. IR (neat): 3405, 2228, 1601 cm-1, 1H NMR (400 MHz,
CDCl3):  7.43-7.19 (m, 7H), 6.94 (d, J= 7.0 Hz, 3H), 3.71 (s, 1H), 3.57 (d, J= 7.1 Hz, 2H), 2.81
(s, 2H), 2.41 (d, J= 61.5 Hz, 4H), 1.94 (s, 2H). 13C NMR (400 MHz, CDCl3):  143.41, 138.08,
129.33, 129.03, 128.39, 127.28, 120.90, 120.77, 117.79, 62.63, 53.09, 49.33, 36.13, MS (ESI+,
m/z) 292.8 (M+1), CHN (expected): C: 78.32, H: 7.26, N: 14.42; CHN (found): C: 78.67, H:
7.21, N: 14.6.
4-(aminomethyl)-1-benzyl-N-phenylpiperidin-4-amine (56)
Compound 55 was added to a hydrogenation vessel along with methanol and a stir bar. The
reaction mixture was stirred until no solid particulates were visible. The stir bar was removed
and a catalytic amount of Raney Nickel was added to the vessel. The vessel was set in the Parr
hydrogenator and the pressure was set to 50 psi. The reaction was monitored via TLC and was
stopped after 24 hours. The Raney Nickel was gravity filtered off through a pad of celite and the
solution was evaporated to a greenish solid. Purification via column chromatography
(DCM/Methanol; 2% methanol gradient) has resulted in yellowish oil. Yield 97%. 1H NMR
(400 MHz, Chloroform-d) δ 7.40 – 7.23 (m, 3H), 7.17 (t, J = 7.7 Hz, 1H), 6.75 (t, J = 7.9 Hz,
2H), 3.52 (s, 1H), 3.42 (s, 1H), 2.89 (s, 1H), 2.63 (d, J = 11.6 Hz, 2H), 2.32 (t, J = 10.6 Hz, 2H),
1.99 (d, J = 13.2 Hz, 2H), 1.65 (t, J = 10.5 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 145.69,
138.08, 129.23, 128.25, 127.12, 118.60, 116.93, 77.48, 77.16, 76.85, 63.18, 54.68, 50.23, 49.08,
33.41.
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tert-butyl (2-(((1-benzyl-4-(phenylamino)piperidin-4-yl)methyl)amino)-2oxoethyl)carbamate (57)
Compound 56 (1.157 mmol), EDCI (1.1 equiv.) and NMM (.5 equiv.) were set to stir in 5 mL
DMF. After 10 minutes, HOBt in NMM (.5 equiv. in 1.6 equiv.) was added. Over an hour
BOC-Gly-OH (1 equiv.) in 1 mL DMF was added to the reaction mixture. The reaction was then
flushed with argon gas and left to stir under argon for 18 hours at room temperature. The
reaction was stopped by pouring it into water then extracted utilizing ethyl acetate (4 times) The
organic layers were combined and extracted once with brine and then dried over sodium sulfate
and evaporated to dryness. Purification by column chromatography (1% methanol gradient)
yielded a white solid. Yield 72%. 1H NMR (400 MHz, Chloroform-d) δ 7.35 – 7.23 (m, 3H),
7.18 (t, J = 7.8 Hz, 2H), 6.79 (dd, J = 31.7, 7.6 Hz, 3H), 6.60 (t, J = 5.0 Hz, 2H), 5.32 (s, 1H),
3.75 (d, J = 5.8 Hz, 2H), 3.58 – 3.50 (m, 4H), 2.61 (d, J = 11.9 Hz, 3H), 2.36 (t, J = 9.9 Hz, 3H),
1.90 (d, J = 13.9 Hz, 3H), 1.75 (t, J = 11.8 Hz, 2H), 1.42 (s, 7H). 13C NMR (101 MHz, CDCl3) δ
169.81, 156.07, 145.19, 137.67, 129.32, 129.19, 128.28, 127.23, 119.45, 117.61, 80.13, 62.87,
54.38, 48.93, 44.45, 33.41, 28.27. MS (ESI+, m/z) 453.4 (M+1).
2-amino-N-((1-benzyl-4-(phenylamino)piperidin-4-yl)methyl)acetamide (58)
Trifluroacetic acid (11.824 mmol, 16.6 equiv.) was added to Compound 57 (.7123 mmol) in
DCM (3mL). The reaction was left to stir for 3.5 hours at room temperature. The reaction was
monitored by TLC. Upon completion of the reaction the solvent was evaporated off.
Purification via column chromatography (5% methanol saturated with ammonia gradient) elution
of desired product between 15-20% methanol saturated with ammonia evaporation of solvent
yielded fluffy white solid. Yield: 99%. 1H NMR (400 MHz, Chloroform-d) δ 7.58 (s, 1H), 7.36
– 7.23 (m, 3H), 7.16 (t, J = 7.7 Hz, 3H), 6.78 (dd, J = 16.9, 7.8 Hz, 5H), 3.55 (d, J = 8.5 Hz, 6H),
3.36 (s, 4H), 3.29 (s, 7H), 2.67 (d, J = 11.8 Hz, 2H), 2.41 (d, J = 10.0 Hz, 4H), 1.93 (d, J = 13.3
Hz, 4H), 1.77 (t, J = 10.3 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 172.47, 145.37, 136.94,
136.39, 129.36, 129.28, 128.36, 127.45, 119.18, 117.45, 62.72, 54.28, 48.84, 45.49, 44.26, 33.15.
MS (ESI+, m/z) 353.3 (M+1).
tert-butyl 1-(1-benzyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa-2,5,7triazaundecan-6-ylidenecarbamate (59)
Compound 58 (2.41 mmol), 1,3,bis (tert-butoxycarbonyl)-2-methyl-2-thiopseudourea (2.89
mmol, 1.2 equiv.), and TEA (6.03 mmol, 2.5 equiv.) were set to stir in DMF (10 mL) under
argon atmosphere at room temperature. Reaction stirred for 70 hours. The reaction was stopped
by pouring into water (approximately ten times volume of DMF) and organic layers were
extracted utilizing ethyl acetate (30 mL, x3). The organic layers were collected and dried over
sodium sulfate. Purification via column chromatography (5% methanol gradient, eluted at 10%
methanol) yielded pale yellow solid. Yield 62%. 1H NMR (400 MHz, Chloroform-d) δ 11.34 (s,
1H), 8.82 (s, 2H), 7.95 (s, 1H), 7.27 (s, 5H), 7.21 (s, 3H), 7.12 (t, J = 7.5 Hz, 4H), 6.79 – 6.62
(m, 7H), 3.97 (d, J = 4.7 Hz, 5H), 3.55 – 3.46 (m, 10H), 2.90 (s, 3H), 2.84 (s, 3H), 2.58 – 2.50
(m, 7H), 2.35 (t, J = 8.9 Hz, 7H), 1.87 (d, J = 12.2 Hz, 5H), 1.77 – 1.67 (m, 7H), 1.62 – 1.27 (m,
31H). 13C NMR (101 MHz, CDCl3) δ 168.54, 163.04, 162.50, 156.24, 152.72, 145.38, 138.11,
129.24, 129.09, 128.19, 127.04, 119.17, 117.34, 83.41, 79.47, 76.88, 62.97, 54.51, 49.06, 45.27,
44.73, 36.43, 33.93, 31.39, 28.25, 28.00. MS (ESI+, m/z) 581.6 (M+1).
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tert-butyl 10,10-dimethyl-3,8-dioxo-1-(4-(phenylamino)piperidin-4-yl)-9-oxa-2,5,7triazaundecan-6-ylidenecarbamate (63)
Compound 59 (1.67 mmol) was dissolved in methanol (100 mL) in hydrogenation vessel. After
Compound 59 was completely dissolved, a catalytic amount of 10% Pd/C was added. The vessel
was then evacuated with hydrogen gas and set to 60 psi. The reaction was monitored via TLC
throughout the reaction time. After 14 days the reaction was stopped by filtration of the catalyst
through a pad of celite. Purification through column chromatography (11-13% methanol eluent)
yielded a white solid. Yield 82%. 1H NMR (400 MHz, Chloroform-d) δ 11.31 (s, 1H), 8.84 (s,
1H), 7.14 (t, J = 7.7 Hz, 2H), 6.82 – 6.59 (m, 3H), 3.98 (d, J = 4.1 Hz, 2H), 3.53 (d, J = 5.4 Hz,
2H), 2.91 (s, 2H), 2.59 – 2.42 (m, 2H), 2.37 – 2.28 (m, 2H), 1.87 (d, J = 12.9 Hz, 2H), 1.70 (d, J
= 8.5 Hz, 2H), 1.47 (d, J = 5.8 Hz, 18H). 13C NMR (101 MHz, CDCl3) δ 168.53, 162.96,
156.29, 152.73, 145.24, 129.31, 119.47, 117.53, 83.54, 79.70, 77.38, 76.75, 54.96, 45.38, 44.81,
41.74, 34.47, 28.27, 28.00.
tert-butyl 1-(cyclopropylmethyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo9-oxa-2,5,7-triazaundecan-6-ylidenecarbamate (64)
Compound 63 (0.244 mmol), bromomethylcyclopropane (0.268 mmol, 1.1 equiv.), and N,Ndiisopropylethylamine (DIPEA; 0.366 mmol, 1.5 equiv.) were set to stir in 3 mL ACN. The
reaction was heated to 80 ºC and left to stir for 24 hours. The reaction was extracted using ethyl
acetate (6 mL, x 3). The organic layers were collected and washed once with brine, once with
distilled water and finally dried over sodium sulfate. All organic layers were collected and
evaporated to dryness. Purification via column chromatography (1% methanol gradient) yielded
a white solid. Yield 33%. 1H NMR (400 MHz, Chloroform-d) δ 11.30 (s, 1H), 8.86 (t, J = 4.3
Hz, 1H), 7.13 (t, J = 7.7 Hz, 2H), 6.92 (s, 1H), 6.76 (d, J = 7.9 Hz, 3H), 4.00 (d, J = 4.8 Hz, 2H),
3.52 (d, J = 5.5 Hz, 2H), 3.08 (s, 2H), 2.90 (s, 2H), 2.59 (d, J = 5.3 Hz, 2H), 2.09 (s, 4H), 1.45
(d, J = 11.8 Hz, 18H), 1.23 (s, 1H), 1.06 (s, 1H), 0.60 (d, J = 7.6 Hz, 2H), 0.25 (d, J = 4.4 Hz,
2H). 13C NMR (101 MHz, CDCl3) δ 168.67, 162.99, 156.14, 152.69, 145.12, 136.39, 129.35,
119.79, 117.88, 83.40, 79.46, 62.42, 54.33, 48.56, 44.67, 32.22, 28.30, 28.00, 6.77, 4.44, 0.97.
N-((1-(cyclopropylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide
(73)
Compound 64 (0.0585 mmol) was combined with trifluroacetic acid (TFA, 0.0261 mol) in 2 mL
DCM. The reaction was set to stir at room temperature for 4 hours after which the solvent was
evaporated off. Purification via column chromatography yield white solid. Yield 93%. 1H
NMR (400 MHz, Methanol-d4) δ 7.30 (d, J = 7.3 Hz, 1H), 7.16 (t, J = 7.7 Hz, 1H), 6.89 (d, J =
7.9 Hz, 1H), 5.03 (s, 10H), 3.95 (s, 1H), 3.53 (d, J = 13.2 Hz, 2H), 3.34 – 3.21 (m, 3H), 3.04 (dd,
J = 14.3, 7.4 Hz, 2H), 2.31 (d, J = 14.4 Hz, 1H), 2.19 (s, 1H), 2.03 (t, J = 12.6 Hz, 2H), 1.29 (s,
1H), 1.14 – 1.08 (m, 1H), 0.73 (s, 1H), 0.41 (d, J = 4.5 Hz, 2H). 13C NMR (101 MHz, MeOD) δ
168.79, 158.01, 144.86, 128.85, 118.83, 116.95, 61.30, 53.46, 45.20, 43.33, 29.85, 5.04, 3.43.
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tert-butyl 1-(neopentyl-4-(phenylamino)piperidin-4-yl)-10,10-dimethyl-3,8-dioxo-9-oxa2,5,7-triazaundecan-6-ylidenecarbamate (65)
Compound 63 (0.3963 mmol), 1-bromo-2, 2-dimethylpropane (0.4359 mmol, 1.1 equiv.), and
Hünig’s base (0.5945 mmol, 1.5 equiv.) were combined in 5mL ACN and set to stir at room
temperature. The reaction was monitored via TLC and determined to be complete after 48 hours.
The reaction was stopped by pouring into ethyl acetate and extracting the organic layers once
with sodium bicarbonate, once with brine and once with water. The organic layers were
combined and dried over sodium sulfate and evaporated to dryness. Purification via column
chromatography yielded a white solid. Yield 25%. 1H NMR (400 MHz, Chloroform-d) δ 11.30
(s, 1H), 9.05 – 8.91 (m, 2H), 7.31 (t, J = 5.9 Hz, 1H), 7.13 (t, J = 7.6 Hz, 2H), 6.80 (d, J = 9.2
Hz, 3H), 4.06 (s, 2H), 3.53 (d, J = 6.1 Hz, 2H), 3.35 (s, 4H), 2.18 (d, J = 6.5 Hz, 4H), 1.45 (d, J =
14.9 Hz, 18H). 13C NMR (101 MHz, CDCl3) δ 168.79, 162.67, 156.08, 152.64, 144.90, 129.38,
119.87, 117.93, 83.54, 80.01, 54.26, 40.08, 30.21, 28.30, 28.00.
2-guanidino-N-((1-neopentyl-4-(phenylamino)piperidin-4-yl)methyl)acetamide (74)
Compound 65 (0.0454 mmol) and TFA (0.0522 mol) in 4 mL DCM were set to stir. The
reaction was monitored throughout the reaction time. After 3 hours the reaction was stopped by
evaporation of solvent. Purification via column chromatography yielded a white solid. Yield
20%. 1H NMR (400 MHz, Methanol-d4) δ 7.37 (t, J = 7.9 Hz, 2H), 7.21 – 7.02 (m, 2H), 4.94 (s,
13H), 4.38 – 4.27 (m, 0H), 4.23 – 4.09 (m, 0H), 4.02 (s, 2H), 3.80 (td, J = 8.5, 3.8 Hz, 1H), 3.66
(s, 2H), 3.54 (dd, J = 6.9, 3.4 Hz, 1H), 3.34 (d, J = 15.5 Hz, 2H), 2.45 – 2.13 (m, 1H), 2.04 –
1.94 (m, 2H), 1.86 (d, J = 8.7 Hz, 3H), 1.82 – 1.72 (m, 2H), 1.60 (s, 0H), 1.29 (s, 1H), 0.96 –
0.86 (m, 1H). 13C NMR (101 MHz, MeOD) δ 169.59, 158.01, 129.24, 124.39, 121.34, 59.87,
43.40, 42.40, 41.86, 37.01, 31.38, 30.81, 19.74.
tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1-(phenylamino)-4-(2H-1,2,3,4-trazol5-ylmethyl)cyclohexyl]methyl}carbamoyl)methyl]amino})methyl]carbamate (66)
Compound 63 (0.400 mmol), potassium iodine (0.0800 mmol, 0.2 equiv.), potassium carbonate
(1.200 mmol, 3 equiv.) and chloromethyltetrazole (0.440 mmol, 1.1 equiv.) were set to stir in 10
mL ACN. The reaction was set to 100 ºC and left to stir for 19 hours after which the reaction
was allowed to cool to room temperature and left to stir for 20 hours at room temperature.
Reaction stopped by evaporation of solvent. Purification attempts through crystallization and
TLC were unsuccessful, taken as crude onto next step. Yield: 75%. 1H NMR (400 MHz,
DMSO-d6) δ 7.84 (s, 0H), 7.02 (s, 6H), 6.77 (s, 6H), 6.55 (s, 3H), 5.74 (s, 1H), 4.10 (s, 7H), 3.88
(d, J = 13.0 Hz, 2H), 3.79 – 3.72 (m, 4H), 3.68 (s, 1H), 3.62 (s, 0H), 3.46 (s, 3H), 3.35 (s, 16H),
3.15 (s, 2H), 3.02 (s, 0H), 2.49 (s, 5H), 2.27 – 2.22 (m, 1H), 2.10 – 2.04 (m, 1H), 1.80 (s, 5H),
1.66 (d, J = 14.7 Hz, 3H), 1.53 (s, 2H), 1.44 (s, 8H), 1.35 (d, J = 6.2 Hz, 7H), 1.22 (s, 1H), 1.10
(s, 1H).
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N-((1-((1H-tetrazol-5-yl)methyl)-4-(phenylamino)piperidin-4-yl)methyl)-2guanidinoacetamide (75)
Compound 66 (0.0956 mmol) and TFA (0.0261mol) in 2 mL DCM were set to stir at room
temperature. The reaction was left to stir for 4 hours afterwards it was stopped by evaporation of
solvent. No further purification attempted. Yield: 30%. 1H NMR (400 MHz, MEOD) δ 8.59 (s,
0H), 7.06 (s, 0H), 6.80 (s, 0H), 6.60 (s, 0H), 4.00 (s, 0H), 3.56 (s, 2H), 2.49 (s, 0H), 1.94 (s, 0H),
1.65 (s, 0H), 1.04 (s, 0H).
tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(pyridin-4ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (67)
Compound 63 (0.400 mmol), 4-bromomethylpyridine (0.480 mmol, 1.2 equiv.), DIPEA (1.763
mmol, 4.4 equiv.) were set to stir at room temperature in 5 mL DMF. The reaction began as a
blood red color and was left to stir for 19 hours after which it was a brownish color. The
reaction was stopped by pouring into ethyl acetate and then water in a separatory funnel. The
reaction was extracted using ethyl acetate (10 mL, x5). The organic layers were combined,
extracted once with brine and once with water then dried over sodium sulfate and evaporated to
dryness. Purification via column chromatography (1% methanol gradient) yielded a pale yellow
solid. Yield: 60%. 1H NMR (400 MHz, Chloroform-d) δ 11.34 (s, 1H), 8.83 (t, J = 5.5 Hz, 1H),
8.54 (d, J = 5.0 Hz, 2H), 7.28 (d, J = 4.6 Hz, 2H), 7.16 (ddd, J = 8.5, 5.6, 1.9 Hz, 2H), 6.80 (t, J
= 7.4 Hz, 1H), 6.77 – 6.68 (m, 2H), 6.52 (dd, J = 8.2, 3.3 Hz, 1H), 3.99 (d, J = 5.2 Hz, 2H), 3.61
– 3.52 (m, 5H), 2.63 – 2.54 (m, 2H), 2.51 – 2.40 (m, 4H), 1.97 – 1.87 (m, 3H), 1.81 (tt, J = 10.3,
6.0 Hz, 2H), 1.47 (d, J = 13.2 Hz, 18H). 13C NMR (101 MHz, CDCl3) δ 168.57, 163.01, 156.35,
152.78, 149.83, 145.21, 129.36, 123.87, 119.54, 117.50, 83.58, 79.63, 54.51, 49.22, 44.86, 33.94,
28.26, 28.01.
2-guanidino-N-((4-(phenylamino)-1-(pyridin-4-ylmethyl)piperidin-4-yl)methyl)acetamide
(76)
Compound 67 (0.0995 mmol) and TFA (0.0404 mol) in 3 mL DCM were set to stir at room
temperature. The reaction was left to stir for 4 hours and stopped by evaporation of solvent.
Purification via column chromatography (1% methanol gradient) yielded a white solid. Yield:
90%. 1H NMR (400 MHz, DMSO-d6) δ 8.86 – 8.79 (m, 8H), 8.00 (d, J = 5.9 Hz, 10H), 7.51 (t,
J = 5.7 Hz, 2H), 7.11 (t, J = 7.7 Hz, 8H), 6.84 (d, J = 8.0 Hz, 8H), 6.75 (d, J = 7.5 Hz, 4H), 4.46
(s, 1196H), 3.82 (t, J = 3.0 Hz, 7H), 3.46 (d, J = 5.3 Hz, 8H), 3.34 – 3.23 (m, 16H), 3.14 (p, J =
1.7 Hz, 5H), 2.14 (d, J = 14.9 Hz, 9H), 1.89 (dt, J = 15.0, 7.6 Hz, 9H), 1.26 – 1.14 (m, 1H), 1.09
(s, 0H), 0.80 (dt, J = 13.1, 6.8 Hz, 1H). MS (ESI+, m/z) 396 (M+1).
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tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(pyridin-3ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (68)
Compound 63 (0.396 mmol), 3-bromomethylpyridine (0.436 mmol, 1.1 equiv.), DIPEA (1.742
mmol, 4.4 equiv.) were set to stir at room temperature in 5 mL DMF. The reaction began as a
pale yellow color and was left to stir for 45 hours. The reaction was monitored via TLC and
upon completion was extracted using ethyl acetate (10 mL, x4). The organic layers were
combined and washed once with sodium bicarbonate, once with sodium hydroxide and once with
water. The organic layers were then dried over sodium sulfate and evaporated to dryness.
Purification via column chromatography (1% methanol gradient) yielded a white solid. Yield:
60%. 1H NMR (400 MHz, Chloroform-d) δ 11.33 (s, 1H), 8.82 (t, J = 5.3 Hz, 1H), 8.53 – 8.44
(m, 2H), 7.68 (d, J = 8.0 Hz, 1H), 7.24 (dd, J = 7.9, 4.8 Hz, 1H), 7.15 (t, J = 7.7 Hz, 2H), 6.75
(dd, J = 31.6, 7.6 Hz, 3H), 6.55 (t, J = 5.7 Hz, 1H), 3.98 (d, J = 5.3 Hz, 2H), 3.53 (q, J = 7.5, 6.6
Hz, 5H), 2.56 (h, J = 7.2, 5.9 Hz, 2H), 2.46 – 2.35 (m, 2H), 1.95 – 1.84 (m, 2H), 1.81 – 1.70 (m,
2H), 1.47 (d, J = 11.6 Hz, 18H). 13C NMR (101 MHz, CDCl3) δ 168.97, 163.42, 156.73, 153.17,
150.76, 149.09, 145.66, 137.15, 129.74, 127.79, 123.76, 119.84, 117.83, 83.95, 80.01, 64.01,
60.44, 54.94, 49.47, 45.23, 34.35, 28.66, 28.42.
2-guanidino-N-((4-(phenylamino)-1-(pyridin-3-ylmethyl)piperidin-4-yl)methyl)acetamide
(77)
Compound 68 (0.0841 mmol) and TFA (0.0337 mol) in 3 mL DCM were set to stir. The
reaction was left to stir for 4 hours and then stopped by evaporation of the solvent. Purification
via column chromatography (1% methanol gradient) yielded a white solid. Yield: 90%. 1H
NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.94 (s, 2H), 8.62 (d, J = 8.1 Hz, 2H), 8.12 – 7.99
(m, 2H), 7.33 – 7.18 (m, 5H), 6.99 (d, J = 8.2 Hz, 4H), 6.90 (s, 2H), 4.58 (s, 3H), 3.98 (d, J = 9.4
Hz, 4H), 3.62 (d, J = 11.2 Hz, 4H), 3.45 (h, J = 9.9, 8.3 Hz, 9H), 3.32 (s, 0H), 2.27 (d, J = 15.4
Hz, 3H), 2.11 (tt, J = 9.4, 5.3 Hz, 5H), 1.41 – 1.27 (m, 1H), 5.21 – 5.16 (m, 1H).
Cycloheptylmethyl methanesulfonate (89)
Cycloheptylmethanol (0.727 mmol), methanesulfonyl chloride (1.090 mmol, 1.5 equiv.), and
TEA (1.381 mmol, 1.9 equiv.), were combined in 5 mL ethyl acetate. The reaction was cooled
to 0 ºC and left to stir for 2 hours. The reaction was monitored via TLC and upon completion
was quenched using sodium bicarbonate. The reaction was extracted using ethyl acetate (10 mL,
x2) and the organic layers were combined and washed once with brine and once with water. The
organic layers were dried over sodium sulfate and evaporated to dryness. The crude product was
taken on without further purification. Yield: 50%. MS (ESI+, m/z) 207.3 (M+1).
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2,2-dimethylpropyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1-(cycloheptylmethyl)-4(phenylamino)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (69)
Compound 63 (0.396 mmol), 89 (0.672 mmol, 1.7 equiv.), potassium carbonate (1.028 mmol,
2.6 equiv.), and potassium iodide (0.0435 mmol, 0.11 equiv.) were combined in 10 mL CAN.
The reaction was heated to 70 ºC and set to stir for 17 hours. Then the reaction was allowed to
reach room temperature and left to stir for 5 hours. The reaction was monitored via TLC and
upon completion was extracted using chloroform (10 mL, x3). The organic layers were
combined and washed once with brine then dried over sodium sulfate and concentrated to
dryness. The crude product was red-orange oil. Purification via column chromatography (1%
methanol gradient) yielded a white solid. Yield 24%. 1H NMR (400 MHz, Chloroform-d) δ
12.10 (t, J = 9.0 Hz, 2H), 8.93 – 8.75 (m, 1H), 8.53 – 8.34 (m, 5H), 7.15 (p, J = 6.5, 6.0 Hz, 7H),
6.83 – 6.68 (m, 10H), 4.08 – 3.87 (m, 7H), 3.82 (dd, J = 18.3, 9.9 Hz, 2H), 3.54 (p, J = 7.4, 6.2
Hz, 8H), 3.36 – 3.25 (m, 2H), 1.76 (tt, J = 11.3, 6.3 Hz, 3H), 1.70 – 1.59 (m, 1H), 1.55 – 1.37
(m, 42H), 1.26 (s, 3H), 1.24 – 1.09 (m, 5H), 0.85 (q, J = 9.4, 8.2 Hz, 2H). Dept 135: 13C NMR
(101 MHz, CDCl3) δ 129.36, 119.31, 117.36, 45.03, 40.45, 37.92, 32.72, 28.40, 28.29, 28.04,
26.20.
N-((1-(cycloheptylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide
(78)
Compound 69 (0.0808 mmol) and TFA (0.0337 mol) in 3 mL CHCl3 were set to stir for 5 hours.
Completion of the reaction was determined by TLC. Purification via column chromatography
(1% methanol gradient) yielded a white solid. Yield 30%. 1H NMR (400 MHz, Methanol-d4) δ
7.54 (s, 1H), 7.50 – 7.42 (m, 10H), 7.34 (d, J = 8.1 Hz, 12H), 4.06 (s, 5H), 3.83 – 3.75 (m, 1H),
3.50 (td, J = 9.6, 4.5 Hz, 2H), 2.35 – 2.30 (m, 1H), 2.24 – 2.18 (m, 0H), 2.09 (s, 7H), 1.98 – 1.89
(m, 3H), 1.89 – 1.80 (m, 5H), 1.55 (d, J = 11.1 Hz, 1H), 1.37 – 1.25 (m, 15H), 0.99 – 0.86 (m,
5H), 0.15 – 0.06 (m, 3H). Dept 135: 13C NMR (101 MHz, MeOD) δ 129.47, 126.85, 123.09,
122.17, 54.24, 47.88, 43.41, 41.86, 41.23, 37.01, 30.86, 30.23, 19.69. 13C NMR (101 MHz,
MeOD) δ 170.00, 160.66, 129.84, 129.47, 123.11, 123.09, 122.64, 122.17, 61.97, 43.41, 41.87,
41.22, 37.02, 37.02, 30.23, 19.69.
Cyclopentylmethyl 4-methylbenzenesulfonate (92)
Cyclopentylmethanol (0.740 mmol), 4-methylbenzene-1-sulfonyl chloride (1.109 mmol, 1.5
equiv.), and TEA (1.405 mmol, 1.9 equiv.) were combined in 5 mL of ethyl acetate and set to stir
at 0 ºC. The reaction was left to stir for 3.5 hours. The reaction was extracted once with sodium
bicarbonate, once with brine and once with water. The organic layers were combined, dried over
sodium sulfate and evaporated to dryness. The crude product was taken on to the next step
without further purification. Yield: 50%. MS (ESI+, m/z) 255.1 (M+1).

75

tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[1-(cyclopentylmethyl)-4(phenylamino)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (70)
Compound 63 (0.398 mmol), 91 (0.677 mmol, 1.7 equiv.), potassium carbonate (1.036 mmol,
2.6 equiv.), and potassium iodide (0.0438 mmol, 0.11 equiv.) were set to stir in 15 mL ACN at
70 ºC. The reaction was left to stir at 70 ºC for 24 hours. Then the reaction was allowed to reach
room temperature and left to stir for 18 hours. The reaction was monitored via TLC and upon
completion was extracted using chloroform (20 mL, x3). The organic layers were combined,
dried over sodium sulfate and evaporated to dryness. Purification via column chromatography
yielded white solid. Yield 12%. 1H NMR (400 MHz, Chloroform-d) δ 7.51 (d, J = 7.7 Hz, 2H),
7.21 (d, J = 7.8 Hz, 2H), 6.98 (t, J = 7.5 Hz, 2), 6.68 – 6.51 (m, 1H), 3.91 (s, 4H), 3.74 (s, 2H),
3.63 (d, J = 11.9 Hz, 1H), 3.49 (d, J = 10.6 Hz, 1H), 3.39 – 3.28 (m, 8H), 2.71 – 2.60 (m, 4H),
2.34 (s, 9H), 2.01 (d, J = 13.8 Hz, 4H), 1.75 (t, J = 12.2 Hz, 1H), 1.67 – 1.53 (m, 4H), 1.36 (s,
18H). 13C NMR (101 MHz, CDCl3) δ 145.26, 143.64, 136.39, 133.06, 129.79, 129.13, 127.60,
119.19, 117.49, 63.60, 58.96, 44.82, 41.71, 33.25, 29.68, 28.06, 21.53.
N-((1-(cyclopentylmethyl)-4-(phenylamino)piperidin-4-yl)methyl)-2-guanidinoacetamide
(79)
Compound 70 (0.0372 mmol) and TFA (0.0404 mol) in 3 mL chloroform were set to stir. After
monitoring via TLC the reaction was left to stir for 4 hours. The solvent was evaporated off.
Purification via column chromatography yielded a white solid. Yield 85%. 1H NMR (400 MHz,
Methanol-d4) δ 7.61 (t, J = 8.9 Hz, 7H), 7.39 (tq, J = 17.3, 7.3, 5.4 Hz, 14H), 7.24 (d, J = 7.8 Hz,
5H), 7.11 (dd, J = 6.6, 3.0 Hz, 1H), 4.00 (s, 4H), 3.66 (d, J = 9.2 Hz, 4H), 3.55 – 3.39 (m, 12H),
3.32 (d, J = 2.4 Hz, 5H), 2.92 (ddd, J = 12.4, 8.9, 3.7 Hz, 5H), 2.59 (tt, J = 13.0, 10.5, 3.9 Hz,
1H), 2.43 (d, J = 6.0 Hz, 11H), 1.94 (tdd, J = 16.4, 13.6, 6.3 Hz, 12H), 1.79 – 1.64 (m, 5H), 1.29
(d, J = 3.8 Hz, 7H). 13C NMR (101 MHz, MeOD) δ 171.83, 159.77, 145.88, 135.08, 131.42,
131.25, 129.10, 124.87, 65.41, 63.10, 45.17, 45.17, 43.58, 43.06, 31.76, 24.61, 21.93.
tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]imino}({[({[4-(phenylamino)-1-(quinolin-8ylmethyl)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methyl]carbamate (71)
Compound 63 (0.347 mmol), 8-(bromomethyl)quinoline (0.381 mmol, 1.1 equiv.), DIPEA
(1.526 mmol, 4.4 equiv.) were set to stir in 5 mL DMF at room temperature. The reaction was
left to stir for 21 hours and progress was monitored via TLC. The reaction was extracted using
ethyl acetate (10 mL, x3); the organic layers were collected and extracted once with brine and
once with water. The organic layers were dried over sodium sulfate and evaporated to dryness.
Purification via column chromatography (1% methanol gradient) yielded a white solid. Yield
59%. 1H NMR (400 MHz, Chloroform-d) δ 11.33 (s, 1H), 8.90 (dt, J = 4.3, 2.0 Hz, 1H), 8.82 (d,
J = 5.6 Hz, 1H), 8.14 (dt, J = 8.4, 2.2 Hz, 1H), 7.92 (s, 1H), 7.76 – 7.68 (m, 1H), 7.58 – 7.49 (m,
1H), 7.39 (ddd, J = 8.3, 4.3, 2.3 Hz, 1H), 7.19 – 7.10 (m, 2H), 6.77 (dt, J = 7.6, 4.0 Hz, 1H), 6.73
– 6.67 (m, 2H), 6.61 (d, J = 5.8 Hz, 1H), 4.35 (s, 2H), 4.02 – 3.95 (m, 2H), 3.59 – 3.53 (m, 2H),
2.84 – 2.76 (m, 2H), 2.63 (d, J = 11.2 Hz, 2H), 1.96 (d, J = 13.9 Hz, 2H), 1.88 (s, 1H), 1.46 (dd,
J = 16.7, 2.3 Hz, 17H). 13C NMR (101 MHz, CDCl3) δ 168.55, 163.02, 156.30, 152.75, 149.46,
146.84, 145.27, 136.35, 129.28, 128.21, 126.40, 120.89, 119.40, 117.50, 83.48, 79.56, 54.34,
49.31, 44.86, 33.84, 28.26, 28.01.
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2-guanidino-N-((4-(phenylamino)-1-(quinolin-8-ylmethyl)piperidin-4-yl)methyl)acetamide
(80)
Compound 71 (0.0675 mmol) and TFA (0.0269 mol) in 2 mL chloroform were set to stir for 4
hours. Reaction stopped upon completion via evaporation of solvent. Purification via column
chromatography (1% methanol gradient) yielded a white solid. Yield: 90%. 1H NMR (400
MHz, Methanol-d4) δ 9.04 – 8.98 (m, 2H), 8.50 – 8.42 (m, 2H), 8.11 (d, J = 8.2 Hz, 2H), 7.94
(d, J = 7.0 Hz, 2H), 7.73 – 7.61 (m, 4H), 7.26 – 7.20 (m, 6H), 6.95 (s, 6H), 4.96 (s, 4H), 4.43 (q,
J = 7.1 Hz, 2H), 3.96 (s, 5H), 3.66 – 3.40 (m, 12H), 2.33 – 2.24 (m, 4H), 2.06 (s, 0H), 1.57 (s,
1H), 1.42 – 1.16 (m, 5H). 13C NMR (101 MHz, MeOD) δ 160.92, 151.77, 147.37, 138.87,
134.41, 131.96, 130.48, 130.12, 128.02, 127.76, 123.48, 118.43, 115.54, 65.66, 44.74, 31.11.
MS (ESI+, m/z) 446 (M+1).
(1H-indol-6-yl)methanol (95)
1H-indole-6-carboxylic acid (3.116 mmol) was dissolved in THF. LAH in THF was added
dropwise with evolution of gas evident. The reaction was left to stir at room temperature under
argon gas for 24 hours. After such time the reaction was cooled to 0 ºC. 10 mL ethyl acetate
was slowly added then 5 mL methanol at which point evolution of gas was evident. The reaction
was left to stir for 1 hour. The reaction was then filtered through a pad of celite with ethyl
acetate wash. The solvent was evaporated off and the residue was dissolved in ethyl acetate and
extracted twice with brine. The organic layers were dried over sodium sulfate and evaporated to
dryness resulting in brown oil. Yield 91%. 1H NMR (400 MHz, Methanol-d4) δ 10.23 (s, 1H),
7.60 – 7.46 (m, 1H), 7.42 – 7.32 (m, 1H), 7.26 – 7.13 (m, 1H), 7.07 – 6.97 (m, 1H), 6.47 – 6.35
(m, 1H), 4.71 (d, J = 15.0 Hz, 2H), 4.09 (d, J = 7.1 Hz, 1H). 13C NMR (101 MHz, MeOD) δ
137.29, 135.05, 128.26, 125.49, 120.81, 119.65, 110.72, 101.89, 65.93.
(1H-indol-6-yl)methyl 4-methylbenzenesulfonate (96)
4-methylbenzene-1-sulfonyl chloride (2.631 mmol, 2.1 equiv.), 95 (1.257 mmol), and TEA
(3.587 mmol, 2.9 equiv.) were combined in 50 mL ethyl acetate. The reaction was set to stir for
4 hours. The reaction was quenched with saturated sodium bicarbonate, and then extracted with
ethyl acetate (x2). The organic layers were extracted once with brine, and once with water. The
organic layers were dried over sodium sulfate and evaporated to dryness. The crude product was
taken on to the next step without further purification. Yield: 50%. MS (ESI+, m/z) 302.1 (M+1).
tert-butyl N-[(1Z)-{[(tert-butoxy)carbonyl]amino}({[({[1-(1H-indol-6-ylmethyl)-4nylamino)piperidin-4-yl]methyl}carbamoyl)methyl]amino})methylidene]carbamate (72)
Compound 63 (0.400 mmol), 96 (0.520 mmol, 1.3 equiv.), potassium carbonate (1.0408 mmol,
2.6 equiv.), and potassium iodide (0.0440 mmol, 0.11 equiv.) were dissolved in 25 mL ACN.
The reaction was set to 70 ºC and left to stir for 48 hours. The reaction was then allowed to
reach room temperature and left to stir for 17 hours. The reaction was monitored via TLC. The
reaction was quenched with water then extracted with ethyl acetate (x1) and chloroform (x2).
The organic layers were combined and washed once with brine then dried over sodium sulfate
and evaporated to dryness. Purification via column chromatography (1% methanol gradient)
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yielded white solid. Yield 14%. 1H NMR (400 MHz, Chloroform-d) δ 7.61 (d, J = 7.9 Hz, 5H),
7.42 (q, J = 6.9, 5.9 Hz, 1H), 7.32 (d, J = 7.9 Hz, 5H), 7.08 (t, J = 7.7 Hz, 5H), 6.70 (dd, J =
21.2, 7.7 Hz, 6H), 4.39 (s, 5H), 3.94 (s, 4H), 3.48 – 3.32 (m, 11H), 2.78 (t, J = 11.3 Hz, 5H),
2.43 (s, 6H), 2.11 (d, J = 14.0 Hz, 5H), 1.71 (ddd, J = 14.9, 11.3, 4.0 Hz, 5H), 1.49 (s, 19H), 1.27
(s, 1H). 13C NMR (101 MHz, CDCl3) δ 145.45, 144.05, 133.07, 130.00, 129.27, 127.74, 119.22,
117.54, 59.90, 54.19, 44.32, 41.94, 33.18, 28.15, 21.55.
N-((1-((1H-indol-6-yl)methyl)-4-(phenylamino)piperidin-4-yl)methyl)-2guanidinoacetamide (81)
Compound 72 (0.0555mmol) and TFA (0.0337 mol) were combined in 3 mL chloroform. The
reaction was left to stir for 2 hours at room temperature. Purification through column
chromatography yielded a pale pinkish solid. Yield 53%. 1H NMR (400 MHz, Methanol-d4) δ
7.63 (d, J = 8.0 Hz, 6H), 7.40 (d, J = 8.0 Hz, 6H), 7.06 (q, J = 7.8 Hz, 6H), 6.66 (dd, J = 14.3,
7.5 Hz, 9H), 3.92 (s, 6H), 3.69 – 3.55 (m, 1H), 3.46 (s, 6H), 3.45 – 3.37 (m, 6H), 2.77 – 2.65 (m,
6H), 2.43 (s, 10H), 2.07 (d, J = 13.9 Hz, 6H), 1.72 (ddd, J = 14.6, 11.3, 4.1 Hz, 6H), 1.35 – 1.27
(m, 4H), 1.18 (t, J = 7.0 Hz, 2H). 13C NMR (101 MHz, MeOD) δ 171.13, 145.43, 134.61,
130.97, 130.69, 128.71, 123.31, 65.67, 61.35, 44.76, 43.13, 31.73, 21.51, 13.98.
In Vitro Experimental
Membrane Preparation
For membrane preparation, CHO cells expressing human NPFF receptors are harvested in
phosphate buffer saline (PBS), frozen at least for 1 h at -70°C, and then homogenized in 50 mM
Tris-HCl, pH 7.4 in a Potter Elvehjem tissue grinder. The nuclear pellet is discarded by
centrifugation at 1,000 g for 15 min at 4°C, and the membrane fraction is collected upon
centrifugation of the supernatant at 100,000 g for 30 min at 4°C. Membranes are aliquoted and
stored at –80°C in Tris 50 mM, pH 7.4 and the protein concentration is determined by the Lowry
method.
[3H]-NPVF and [3H]-EYF are custom-made by RC TRITEC AG (Teufen, Switzerland)
by hydrogenation of the unsaturated peptide precursors with 99% tritium gas. Tritiated products
are purified (> 98%) by HPLC and dissolved in ethanol to obtain 1 mCi/ml (37 MBq/ml).
Binding Assay
Binding of [3H]-NPVF and [3H]-EYF is measured by rapid filtration. Membranes (5-15
µg protein) are incubated in polypropylene tubes in a final volume of 500 µl containing 50 mM
Tris-HCl, pH 7.4, 0.1% bovine serum albumin, 60 mM NaCl (for NPFF2 receptors only), the
radioligand at 0.5-1 nM and compounds to be tested at the desired concentration. After 1 h
incubation at 25°C, samples are rapidly filtered on Whatman GF/B filters preincubated in 0.3%
polyethylenimine. The filters are rinsed three times with 4 ml of ice cold buffer containing 0.1 %
bovine serum albumin, and the bound radioactivity is counted in a liquid scintillation
spectrophotometric counter (50 % efficiency, Packard).
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In Vivo Experimental
Formalin Assay
Animals: Male Swiss Webster mice (20-30 g) from Harlan Laboratories (Harlan, IN,
USA) were used for the experiments. The mice were housed in groups of five with a 12 h
light/12 h dark cycle. Food and water were provided ad libitum. All mice were randomly
selected for each treatment group. Procedures involving animals were performed according to
the guidelines approved by the Institutional Animal Care and Use Committee (IACUC).
Drugs and Route of Administration: Morphine (Sigma-Aldrich, Milwaukee, WI) was
dissolved in saline (0.9% NaCl) and prepared the day of the experiment. 10% Formalin (Sigma
Diagnostics Accustain: 10% formalin solution in neutral buffered AFIP; Sigma-Aldrich,
Milwaukee, WI) was diluted using saline to the appropriate concentration at the prior to the
beginning of the experiment. Pretreatment of morphine (i.p.) or saline (i.p) occurred 15 minutes
prior to formalin injection (10 µL, intraplantar).
Testing Procedures: At least one hour prior to testing animals were acclimated to the
testing environment. Animals were weighed day of test and acclimated to individual testing
chambers (16 X 16 X 16 Plexiglas chamber; San Diego Instruments, San Diego, CA) for 30
minutes. 15 minutes into acclimation to the chamber mice were pretreated with saline (1 mg/kg,
i.p.) or morphine (5 mg/kg, i.p.).
At the end of the 30 minute acclimation the animal was dosed intraplantar with 10 µL of
formalin (0.1, 0.2, 1, or 5%). The mouse was returned to the chamber where locomotor activity
was measured and observation of licking or biting of injected paw (established manifestations of
pain) as a function of time engaged in behavior. The time of the behavior was measured in five
minute increments for a total of one hour post formalin injection. Locomotor activity was
automatically monitored for 60 min. Total activity was expressed as the total number of
interruptions of 16 cell photo-beam chambers.
Statistical Analysis: All values are expressed as Mean ± SEM with n= 10 animals/group.
All data were analyzed using one way ANOVA followed by Dunnett's post hoc test to determine
significant difference from saline control at * p < 0.05, ** p< 0.01, and *** p< 0.001.
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IUCAC APPROVAL DOCUMENTS FOR FORMALIN ASSAY

ANIMAL STUDY PROTOCOL APPLICATION
____________________________________________________________
_________

FOR OBSERVATION-ONLY STUDIES:
COMPLETE THE DETERMINATION OF EXEMPTION FOR OBSERVATION-ONLY STUDIES FORM AT

http://www.research.olemiss.edu/iacuc/forms

MANDATORY FOR ALL PROTOCOL APPLICATIONS:
◦
◦
◦

Submit an electronic copy to askiacuc@olemiss.edu and fax or email completed and
signed signature page to ext. 7577 (or deliver signature page to 100 Barr Hall).
Applications will not be sent out for review until signature page is received in IACUC
office.
No research may begin until written final approval is received.
IDENTIFY ANY PROPRIETARY INFORMATION SO IT CAN BE REDACTED
FOR COPY REQUESTS UNDER THE MISSISSIPPI SUNSHINE LAW

SUBMISSION CHECKLIST

DID YOU:
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SIGN AND DATE YOUR APPLICATION FORM, SUBMIT AN ELECTRONIC COPY AND
FAX/EMAIL SIGNATURE SHEET OR DELIVER ONE SIGNED COPY TO THE IACUC OFFICE?

HIGHLIGHT ANY PROPRIETARY INFORMATION?

CONSULT WITH THE ATTENDING VETERINARIAN FOR CATEGORY C AND D
PROTOCOLS?

ATTACH APPLICABLE APPENDICES?

ATTACH A DATA COLLECTION FORM [FOR APPENDIX VII]?

OBTAIN RADIATION SAFETY APPROVAL, IF APPLICABLE?

OBTAIN IBC APPROVAL [FOR PROJECTS USING BLOOD, FLUIDS OR TISSUES]?

ATTACH APPROVAL LETTER/S AND/OR PERMITS FROM STATES, OTHER IACUCS OR
OTHER PARTICIPATING INSTITUTIONS?

ATTACH STANDARD OPERATING PROCEDURES, IF APPLICABLE?

OFFICE USE ONLY
Species:

Number of Animals:
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Pain & Distress Category:

PI:

Protocol #:

Title:

12-018
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ANIMAL STUDY PROTOCOL APPLICATION

A. Administrative Data [text boxes will expand]

1. Project Title: Set-up and Evaluation of Formalin Test in Mice

2. Principal Investigator [only faculty, post-doctoral student, or staff may submit an application]:

Name: Christopher McCurdy Department: Medicinal Chemistry Telephone: 915-5882
Email: cmccurdy@olemiss.edu

3. Animal Protocol Director [person directing animal study if other than PI]:

Name: David B. Murray
dmurray@olemiss.edu

4. Student Project:
N/A

Department: Pharmacology Telephone: 915-7330

Dissertation

Thesis

N/A

Email:

Undergraduate [including Honors College]

Student name: Jessica Mankus Department: Medicinal Chemistry Telephone: 915-1663
jvmankus@olemiss.edu

5. Funding Information:

Other:

Email:

N/A

Funding Agency/Organization: NIGMS

Grant/Contract No: 9P20GM104932

PI on Grant/Contract: Stephen J. Cutler
2012

Project Period: 12 / 22 / 2011 to 6 / 30 /
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6. Protocol Type:

Research

7. Protocol Category:

New

Breeding

Teaching

Other:

Continuation of Protocol #:

8. Suggested Pain and Distress Category: D

9. Personnel Working with Animals on this Project:
Role Involving
Animal Use
[Be specific. An “X,” “All”
or “Yes” is not an
acceptable description of
personnel responsibilities.]

Name

Departme
nt

Phon
e

Monit
or
anima
ls

Email

[Feeding
,
breeding
, etc.]

PI

Medicinal
Chemistry

5882

cmccurdy@olemiss.
edu

David
Murra
y

Pharmacolo
gy

7330

dmurray@olemiss.
edu
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Conduct
Experimen
tal
Procedure
s

Describe
specific
training &
expertise
[Identify trainer
and include brief
outline of
expertise/
qualifications of
person to train
others.]

[Surgery*,
blood draws,
etc.]

Will assist in
conducting
and/or
supervising
experiments
as
necessary.

IACUC
Approv
ed
[Check
‘yes’
ONLY if
they have
completed
all
required
training
and are
approved
to work
with
animals]

Will not be
involved in
conducting
experiments.

Yes
No

Dr. Murray has
14 years
experience
working with
rodents.
Developed and
perfected
Millar
catheterization
procedure, trai
ned in basic
animal
handling,

Yes
No

blood, and
tissue
collection,
arterial and
venous
catheterization,
and general
rodent survival
surgery at East
Carolina
University
SOM, Auburn
University
CVM,
University of
South Carolina
SOM, and the
University of
Mississippi.
Lisa
Wilso
n

Pharmacolo
gy

7330

llwilso1@olemiss.e
du

Lisa will
conduct
behavioral
experiments
, inject
animals,
draw blood,
and dissect
tissue.

Dr. El-Alfy has
trained Lisa.
She has six
years
experience
conducting in
vivo animal
experiments.

Yes
No

Jessica
Mank
us

Medicinal
Chemistry

1663

jvmankus@olemiss.
edu

Jessica will
conduct
behavioral
experiments
, inject
animals,
draw blood
and dissect
tissue.

Lisa Wilson
trained Jessica.
She has oneyear
experience
conducting
behavioral
experiments.

Yes
No

*Surgery requires 1) training and 2) technique performance approval by Dr. Fyke. Submit ‘Proficiency Criteria
for Research Animal Surgery’ form to Dr. Fyke, B104 NCNPR.

10. Personnel Responsible for Animal Care:

N/A Explain:
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Name

Phone

Animal Care [Required: check personnel
responsible for each]

Email

Daily
David
Murray

7330

dmurray@olemiss.edu

Lisa Wilson

7330

llwilso1@olemiss.edu

Jessica
Mankus

1663

jvmankus@olemiss.edu

Dr. Harry
Fyke

9155324

hfyke@olemiss.edu

Weekend

Holiday

Emergency

11. Location/s where Animals Will Be Housed or Procedures will be Performed [check with Animal
Facility Supervisor about available space and indicate whether animals will be housed for more than 12
continuous hours for each area]:

N/A Explain:
Building(s)/Room(s) Number: TCRC B070, TCRC B064, TCRC B050, TCRC B049, TCRC B039, TCRC 042, TCRC 040
>12 hours
Yes
No
Building(s)/Room(s) Number:
>12 hours
Yes
No
Building(s)/Room(s) Number:

>12 hours

Yes

No

Other Participating Institution:

B. Overview and Rationale of Study

It is generally not the responsibility or intent of the IACUC to review protocols for scientific merit.
The following information is required to assist the committee in evaluating the relevance of the
animal model and procedures to be used.

1. Briefly describe the general experimental design and procedures [This should be no more than
ONE PAGE and written at HIGH SCHOOL LEVEL or for non-scientists. DO NOT USE JARGON.
DEFINE ABBREVIATIONS and ACRONYMS. This description should allow readers to understand
what happens to an animal from its entry into the experiment to the endpoint of the study. The
details of specific animal procedures, such as injection sites, surgery, and anesthetics are not
required here.]: The formalin test affords a model of chronic pain. While analgesic effects of compounds can
be monitored through transient pain assays such as hot plate and tail-flick, neither offers a measure of chronic
pain relief. As chronic pain has long-term costs and strong clinical relevance an authentic animal model is a
necessary asset. Initially the formalin test was done with cats and rats, however, recent adaptations of the test
allow for use of cost-effective mice as the model animal. Twenty-four hours prior to testing mice are
acclimated in the locomotor chambers for one hour. On test day mice are acclimated to the room for one hour
and to the locomotor chamber for thirty minutes prior to the first injection. The initial injection of saline or
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other vehicle, morphine, or unknown compound will be given systemically (intraperitoneal injection) then ten to
fifteen minutes later (depending on compound) formalin (at varying percentages e.g. 0.1%, 1%, 5%) will be
injected to the dorsal left hind paw. After the formalin injection the mouse will be observed for behaviors such
as licking or biting of injected paw. These behaviors will be measured for set time periods and recorded in time
mouse is performing behavior. The total time the mouse is involved in the experiment is expected to be one
and one-half hours. Paw biting or licking are considered manifestations of pain for the purpose of this test.
Locomotor activity may also be collected as a secondary measure of pain. We will be using a modified version of
SOP entitled Rodent Formalin Test provided by Dr. Ken Sufka. We will be verifying and adjusting the formalin
concentration to fit our specific needs--mainly a clear biphasic response with the lowest possible formalin
concentration.

2. Briefly state the rationale/purpose and significance of the project [This should be no more than
ONE PAGE and written at HIGH SCHOOL LEVEL and for non-scientists. DO NOT USE JARGON.
DEFINE ABBREVIATIONS and ACRONYMS.]: Certain assays such as hot plate and tail-flick measure
transient pain. However, these assays are unable to evaluate chronic pain. The formalin test offers an
opportunity to measure the effectiveness of potential analgesic agents. The formalin test provides a clinically
relevant scenario of chronic pain. Since current pain treatments of pain especially chronic pain are ineffective,
have low patient compliance, or have adverse outcomes such as high addiction potential new analgesic agents
are needed to fill this void. The formalin test allows for testing of analgesic agents in a chronic pain
environment.

3. Duplication of Research [enter information in table below]:
Database
Used

Publication Years
Covered
From

ALTWEB

1980

Key Words

Date of
Search

Search Results

To
2011

Alternative
to formalin
assay;
Alternative
to chronic
pain model

5/7/2012

Duplication is necessary
because:

SciFinder
Scholar

1987

2012

Alternative
to: formalin
test, formalin
assay,
chronic pain
model

5/7/2012

PubMed

1979

2012

Alternative
to: chronic

5/7/2012
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No duplication

pain model,
formalin
assay;
formalin
assay;
chronic pain
and formalin

4. Animal Model/s:
*No. of
Animals
for 3 yr
period
1600

Genus/Species

Mouse

Strain, Stock
or Breed

Swiss Webster

Age and/or
Size

25-40 grams

Sex

Daily Census**
Average

Male

160

High

280

* If breeding protocol, put number you are requesting to maintain at any given time.
* If field study, give your best approximation.

**During the times animals will be housed, list the average and estimated high # of animals to be housed on
any given day

5. Provide rationale for choice of animal model/s: Male Swiss Webster mice are commonly used for the
formalin test where mouse is the species of choice.

6. Justify Animal Numbers: Justification for animal numbers should be thoroughly supported by
current resources. Information collected from (your and/or previous) research, during
conferences, from journal articles, and through database searches can help provide statistical
justifications and sound rationale for the number of animals used: Number of Swiss Webster mice
needed to evaluate natural product or synthetic compounds for analgesic effects:
number of compounds to be tested = 20 / year (2 & 3)
number of doses per compound = 4 (+3 standards per compound tested)
number of tests per compound = 1
number of mice per dose = 10
number of mice per year (2 & 3) = 20* 7* 1* 10 = 1,400 mice
number of compounds to be tested = 2 (year 1)
number of doses per compound = 8
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number of tests per compound = 1
number of mice per dose = 10
number of mice per year (year 1) = 2* 8* 1* 10 = 160 mice

G*Power Analysis suggests a sample size of 13 for one-tail t-test and 16 for a two-tail t-test; therefore, in order
to have some overlap we will utilize a sample size of 15. While for the first year we only expect to see a
decrease in number of licks (how we intend to measure pain perceived), during the second and third years when
more unknown compounds are tested it may create a hypersensitive response (an increase in number of licks).
Thus utilizing a sample size of 15 will be able to cover an increase or decrease in pain perceived.

From G*Power (v. 3.1.3):
t tests - Correlation: Point biserial model
Analysis:

A priori: Compute required sample size

Input:

Tail(s)

= Two

Effect size |ρ|

= 0.7071068

α err prob

= 0.05

Power (1-β err prob)

= 0.95

Noncentrality parameter δ

= 4.0000002

Critical t

= 2.1447867

Df

= 14

Total sample size

= 16

Actual power

= 0.9602208

Output:

t tests - Correlation: Point biserial model
Analysis:

A priori: Compute required sample size

Input:

Tail(s)

= One

Effect size |ρ|

= 0.7071068

α err prob

= 0.05
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Output:

Power (1-β err prob)

= 0.95

Noncentrality parameter δ

= 3.6055515

Critical t

= 1.7958848

Df

= 11

Total sample size

= 13

Actual power

= 0.9579145

References for G*Power:
Faul, F., Erdfelder, E., Buchner, A., & Lang, A.-G. (2009). Statistical power analyses using G*Power 3.1: Tests for correlation
and regression analyses. Behavior Research Methods, 41, 1149-1160.

Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible statistical power analysis program for the
social, behavioral, and biomedical sciences. Behavior Research Methods, 39, 175-191.

7. Name of animal supplier or field location: Harlan

8. Animal Type [REQUIRED: Animals will be quarantined upon arrival. Submit animal health status
report.]:

In-house transfer [approved form on file]

Wild caught – [complete Appendix III]

Bred in-house

Captive bred

Purpose bred

From other institution/s [provide

name]:

9. Is anything other than routine care and equipment required?
No

Solid bottom cages
Special diet

Laminar flow room
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Yes – complete checklist

Unique light

Filter tops

Autoclave feed, bedding and cages

Individual housing

Treated water

Wire bottom cages: Justify:

Clarify if necessary and/or list other requirements:

10. Describe the cleaning procedures and schedule for animal enclosures not in the vivarium,
including person responsible for their maintenance. Provide justification if cleaning intervals
exceed 2 weeks.
N/A: Vivarium Housing
N/A Explain:

11. Will animals be physically restrained longer than one hour in a conscious state?
Yes – complete table & justify

Species

Purpose

No – proceed to #13

Type of Restraint

Frequency

Duration

Justify duration of restraint:

12. How will animals be monitored while they are restrained? [Attach form for monitoring
physically restrained animals]:

13. Have any of these animals been previously used in an experimental procedure or another
protocol?
Yes – list species and explanation below

Species

Explanation

142

No

14. Will you be administering a substance?

Yes – complete table below

No

Species

Substance
Administered

Dose(s)*

Route(s) of
Administration*

Frequency

Volume

Agents
unknown/not
previously
tested in vivo

Mice

Saline (vechile)

1 mg/kg

i.p., p.o.

1X

20 L

Mice

1 cremphor: 1
ethanol: 18
saline (vechile)

1 mg/kg

i.p, p.o.

1X

20 L

Mice

Morphine

220mg/kg

i.p., p.o.

1X

20 L

Mice

Delta-9 THC

0.1-40
mg/kg

i.p.

1X

20 L

Mice

Formalin

0.1 -5 %

s.c.

1X

20 L

Mice

Natural
products, with
potential
analgesic
profile

0.1-30
mg/kg

i.p., p.o.

1X

20 L

X

Mice

Synthetic
potential
analgesic
agents

0.1-30
mg/kg

i.p., p.o.

1X

20 L

X

*List all likely doses and routes that may be used

15. Will food and water be provided ad libitum?
Yes
assessment methods

Species

No: list species, explanation, and a description of health and well-being

Explanation

Description of assessment
methods
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16. Is it likely animals in this protocol will experience pain or distress?
No – proceed to #18
Yes – explain and list methods to minimize pain and
distress: The formalin test is a measure of chronic pain therefore minimization of pain will not be possible
during the time of testing. However discomfort caused by the formalin is limited and duration after one hour is
lessened. Distress to the mouse will be reduced by acclimation of the mouse to the testing apparatus as well as
minimal sensory stimulation (e.g. constant room temperature, minimal noise, etc.) outside what is caused by
the assay.

17. Justify unrelieved severe or chronic pain and distress: In order to discover if the compound being
tested relieves chronic pain, pain cannot be relieved during the testing period. Initial tests during year one will
help to determine the optimal and minimum formalin concentration that elicits a clear biphasic pain response,
as is characteristic of the formalin test. Once this concentration is determined all future tests will only use one
concentration of formalin and there for will provide the least possible stressful environment while still creating
a valid model of chronic pain.

18. REQUIRED: Conduct literature search for alternatives [ways to reduce numbers of animals
used, replace animal model, or methods to refine the study to lessen or eliminate pain or
distress]:
◦
◦
◦

Date search conducted: 5/7/2012
Publication years covered: 1979 to 2012
Keywords/search strategy used [List keywords used to conduct your search using
terminology from your responses to the above, e.g., alternative, in vitro, in vivo, exvivo, assay, technique, cell culture, cultured cells, tissue culture, simulation, animal
testing alternative, non-animal model, etc.]: alternative to chronic pain model, alternative to
formalin assay, chronic pain and formalin, formalin assay, alternative to formalin test.

19. Databases searched/sources consulted for alternatives:

This site must be included in the search:

ALTWEB [http://altweb.jhsph.edu]

Also choose from one or more of the following:
ASFA
EMBASE

AWIC
FEDRIP

AGRICOLA

BIOSIS
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CAB

Current Contents

Google Scholar
Life Sciences
PsycINFO
TOXLINE

SciSearch / Web of Science
SciFinder Scholar

MEDLINE (PubMed)

NTIS

Pascal

Other specialized databases and web resources (specify):

20. List any potential alternatives of which you are aware [e.g., alternate models, modified
techniques, housing modifications, modified restraint, in vitro methods, computer simulations,
etc.]: No clear alternatives exist for this assay. Other chronic pain models involve spinal surgical procedures.

21. Did you find any ways to reduce animal numbers? Initial work done in year one to determine the
minimum optimal formalin concentration will help to reduce animal numbers in the subsequent years. Likewise
test compounds can be verified as having analgesic properties (through hot plate and tail-flick assays) prior to
testing in the formalin assay. This can limit the number of animals tested.

22. Did you find any methods that minimize pain or distress? By initially testing and verifying the
concentration of formalin that produces a clear bi-phasic model we will be refining the assay as to minimize pain
and distress for the animals.

23. Can you replace your animal model with a non-animal model or less sentient species?
Why or why not? At this time no in vitro or non-animal models exist as viable alternatives to behavioral
pain models such as the formalin assay. In order for a pertinent assessment of chronic pain, a living model that
has sensory input from the extremities to brain and measurable reactive behavior must be used and at this
point cannot be created outside an animal model.

24. Will you be using non-pharmaceutical grade drugs?
No
Yes – List each drug, its
intended use, and provide justification [contact Attending Veterinarian (x5324) for ordering
information]: The natural products to be tested in the assay may not be pharmaceutical grade due to the
limited quantities extracted from the source such as plant or marine sponge.

25. Biological Fluids Collection:
A. Will biological fluids be collected? [e.g., blood, lymph, bile, cerebrospinal fluid, urine,
etc.]
Yes – complete table below

No – proceed to #26
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Species

No

Fluid

Volume

Collection
frequency

Collection
site

Anesthetic

B. If fluids are collected, will animals survive the fluid collection procedure?
N/A

Dose

Yes

26. Disposition of Animals (REMINDER: Multiple surgeries require justification.):
Will animals be euthanized?
Yes – Describe method(s)* by species to be used, including dose and route (if
applicable): Mice will be euthanized by CO2 asphyxiation. Because CO2 asphyxiation is utilized as the primary
method for euthanasia, a secondary method such as cervical dislocation will be used to ensure death.

*If CO2, a secondary method of euthanasia to ensure death MUST be used and described above.

No:
Transferred to breeding protocol # _________
Transferred to another research protocol # _________
Other:

27. Disposal of animals that die while on study:
Other:

Freeze

Refrigerate

Do not save

28. Humane Endpoints - Ideally, humane endpoints (predictive signs, indicators of an irreversible
deteriorating condition) should be established prior to beginning animal work. Realizing the difficulty in
predicting these for studies which involve compounds with unknown adverse effects, PIs should try to
develop humane endpoints if severe pain, severe distress, or death is observed. Guidelines should be in
place to euthanize animals when humane endpoints are reached, when the study objectives have been
realized, if it becomes clear that they cannot be realized, or whenever the degree of suffering is not
required or justified by the protocol.
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A. Explain how animals with severe responses will be handled. All animals will be frequently
monitored for any signs of severe distress. The assay focuses on compounds that could be potential
medications. Therefore documenting any severe side effects is an essential part of the testing.
Consequently all animals will go through the whole test session (animal monitoring criteria are
attached).

B. List signs of pain and distress severe enough to indicate the need for euthanization. Any
animal showing unusual distress or pain (outside of the parameters of the experiment) such as extreme
loss of body weight, unusual vocalization when handled, poor grooming or gasping will be euthanized.

C. State the method of euthanasia if different from 25 above.
above

N/A: Same as

29. Is death, not resulting from euthanasia of any animal subject, an endpoint in any of the studies
in your project?
No
Yes – provide scientific justification:

30. CHECKLIST:
A. Experimental Disease Induction: Will animals be inoculated for experimental purposes?
No

Yes – complete Appendix I

B. Tumor Induction: Will animals be inoculated with tumor cells?
No

Yes – complete Appendix II

C. Wild Caught Animals: Will wild caught animals be obtained for this study?
No

Yes – complete Appendix III

D. Radioisotopes, Toxic Chemicals, or Biological Hazards: Will personnel be exposed to
radioisotopes,
carcinogens, or infectious agents?
No

Yes – complete Appendix IV

E. Surgical Procedures: Will survival or non-survival surgical procedures be performed?
No

Yes – complete Appendix V

F. Novel Compounds: Will any new or unknown drugs, compounds, or biological extracts be
used in this
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protocol?
No

Yes – complete Appendix VII

C. Investigator Assurance

or
N/A This application does not diverge from methods/procedures in the full grant
application (if project
is funded).

The information provided in this protocol form accurately reflects the intended use
of animals for
this research or teaching activity.

or
N/A I have consulted with the Attending Veterinarian regarding any experiments that
are classified in
pain and distress categories C or D.

Any changes in procedures will not be undertaken without prior notification and
approval of the
Institutional Animal Care and Use Committee.

The activities described in this study do not unnecessarily duplicate previous
experiments.

Prior to participation in the protocol, all persons listed/involved in the use of
animals on this
protocol:

◦
◦

Have been informed of the experimental objectives and methods.
Have received/will receive training in the execution of animal-related
procedures he/she will perform and will participate in any educational or
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◦

training programs deemed appropriate or necessary by the IACUC, including
the mandatory training for research animal surgery.
Have met/will meet the requirements of The University of Mississippi
Occupational Health Program.

I agree to use appropriate anesthesia and/or analgesia to relieve pain/distress
whenever use of
these agents will not jeopardize the scientific validity of the data.

I have read the Guidance on Humane Endpoints and agree to follow it to minimize
pain, distress or
illness in laboratory animals.

I will take appropriate steps to avoid exposure of project personnel to hazardous
agents in the
study.

If the IACUC approves my application, I agree:

◦
◦
◦

To execute this work as described.
To comply with the guidelines set forth by the IACUC and The University of
Mississippi’s Department of Health and Safety.
To be responsible for the supervision and work of my staff.

I agree to comply with the requirements of the following:

◦
◦
◦
◦

Public Health Service Policy on Humane Care and Use of Laboratory Animals.
Provisions of the USDA Animal Welfare Act and Regulations.
UM’s policies governing the use of animals in research, testing, or teaching.
The Guide for the Care and Use of Laboratory Animals.

State the reason/s if you cannot agree to any of these statements:

SIGNATURES
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Department

_______________________________________________
______________________________________
Principal Investigator / Project Director

Date

_______________________________________________
______________________________________
Department Chair

Date

IACUC Approval

_______________________________________________
______________________________________
IACUC Chair

Date
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_______________________________________________
______________________________________
Attending Veterinarian

Date
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STANDARD OPERATING PROCEDURES
The University of Mississippi Institutional Animal Care and Use Committee

OFFICE USE
ONLY
SOP No.

Date Submitted:

Full Committee
Review Date:

Yr. 2 Review:

Yr. 3 Review:

Approval Date:

INSTRUCTIONS: Submit one completed form electronically askiacuc@olemiss.edu AND an
electronic version of the signed copy (faxed to 915-7577)

Title: Rodent Formalin Test

Author/s:
Dr. Ken Sufka

Purpose and Scope: This SOP describes the materials and procedure used in
testing inflammatory nociception in rodents
Materials and Equipment Needed (if appropriate):
Plexiglas observation chambers

Syringe, cloth towel &

Required or Specialized Personnel Training on Procedure: Before beginning
work with animals all personnel are required to meet all University of Mississippi
Occupational Health and Safety Program (OHSP) standards for conducting
research with animals. This includes submission of OHSP health forms, OHSP risk
inventory, safety training through the Health and Safety Department (including
chemical, biological, hazardous waste disposal, carcinogenic, and radiological), as
well as online training courses through the University of Mississippi for working with
rodent species. Also, all personnel are trained in the proper method for
intraplantar injections into rodents.
Safety Concerns (if appropriate): Compliance with vivarium standards of dress
will be followed by all laboratory members to assure safety of personnel and
animals. Lab members will be trained in all procedures to be conducted within the
lab including the specific procedures for modeling pain in rodent species.
Make
sure animal is properly restrained during injection. Make sure that animal is
injected properly with minimal discomfort.
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Definitions:

IPL: Intraplantar injections: injections into the footpad.

Procedural Steps: The animal is removed from its home cage, gently restrained in a soft
towel. One hindlimb is gently pulled out from the towel and is injected with a 5% formalin solution
in the footpad (note: this is formalin and not formaldehyde). For mice the formalin volume is 25 l
and for rats is 50 l. The animal is placed in an observation cage and pain-related behavior is
observed for up to one hour. Behaviors of interest are: for mice: frequency and/or duration of
soft biting/licking affected foot; for rats: frequency and/or duration of favoring, lifting and soft
biting/licking affected foot. After the observation period the animal is returned to home cage.

IPL injections of formalin at such concentrations are designed to produce a longer lasting
nociceptive response than the acute thermal or mechanical nociceptive tests. It should be noted
that formalin-induced pain related behaviors diminish significantly over the course of the 1 hr
observation period and are all but absent within a couple of hours of administration (e.g., some
favoring can be detected at such time points). Further, the concentrations employed do not
produce self-mutilation nor lesions of the affected footpad. Rodents are used only once in such
assays are sacrificed after testing.
Records to be Kept: Records of behaviors observed
Identification and Emphasis of “Critical Steps” in Procedure:
formalin into the footpads of animals.

Proper injection of

Copies of forms to be used, drawings of apparatus, tables, figures, etc.:

n/a

References, i.e. operating manuals, published techniques, other SOPs, etc.:

Mogil JS, Wilson SG, Wan Y (2001) Assessing nociception in murine subjects. In: Kruger L,
editor. Methods in Pain Research. Boca Raton: CRC Press. pp. 11-39.
Sufka KJ, Watson GS, Nothdurft RE, Mogil JS (1998) Scoring the mouse formalin test:
validation study. European Journal of Pain, 2, 351-358.
Watson GS, Sufka KJ, Coderre TJ (1997) Optimal scoring strategies and weights for the
formalin test in rats. Pain, 70, 53-58.
Vierck CJ (2005) Animal models of pain. In: McMahon SB, Koltzenburg M, Wall PD, editors.
Wall and Melzack's textbook of pain 5th ed. Edinburgh: Elsevier Churchill Livingstone.
pp. 175-186.

SIGNATURES
Author/s:

Date:
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APPROVAL SIGNATURES
IACUC Chair:

Date:

Attending Veterinarian:

Date:

SOP # _________________
Page PAGE 1 of NUMPAGES1
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Appendix VII – Novel Compounds
(For policy, see IACUC Policies at http://www.research.olemiss.edu/iacuc/policies)

1. Provide compound names if known and not proprietary (optional):

2. Which of the three following classes applies to the compound(s)?

In vitro or in vivo data exist and indicate no known toxicity.
In vitro or in vivo data exist and indicate probable toxicity – submit information with protocol
application.
[This information can come from testing the compound in question or compounds with similar structure. It may
include information such as chemical class (stimulant, depressant, etc.), mechanism/site of action, or
cytotoxicity.]
There are no In vitro or in vivo data available.

3. Provide the literature or structure search strategy that was used to determine class: Not possible at this
time; compounds will need to be isolated or synthesized first.

4. For each box checked in 2 above, describe and indicate your procedures for determining the following:

Initial dose

Route of
administration

Intervals for
increasing the
dose [e.g., half log]

1mg/kg

i.p., p.o.

log units
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Reasons for
deviating from the
plan

Rationale for
target dose [e.g.,
adverse effects
and/or dose needed
to treat the disorder]
we will begin with
the lowest possible
does because of the
nature of the
compounds being
tested (i.e. no prior
in vitro or in vivo
data). Moreover the
animals will be
closely monitored to
guard against any
toxicity. Further

doses will be
evaluated in a dose
response method in
the assay.

5. Establish a data collection procedure for monitoring animals on the treatment, and attach it to

this protocol.
This procedure should include an observational checklist of signs of pain and distress in the
species in this study, and the frequency of observations to be made during the treatment
period.

6. List personnel who will monitor the animals. Indicate the training/background that provides
them with the expertise to do this. Lisa Wilson (Dr. El-Alfy has trained Lisa. She has six years
experience conducting in vivo animal experiments.) Jessica Mankus (Lisa Wilson trained
Jessica. She has one-year experience conducting behavioral experiments.) Dr. Murray has 14
years experience working with rodents. Developed and perfected Millar catheterization
procedure, trained in basic animal handling, blood, and tissue collection, arterial and venous
catheterization, and general rodent survival surgery at East Carolina University SOM, Auburn
University CVM, University of South Carolina SOM, and the University of Mississippi.

7. Ideally, humane endpoints (predictive signs, indicators of an irreversible deteriorating
condition) should be established prior to beginning animal work. Realizing the difficulty in
predicting these for studies which involve compounds with unknown adverse effects, PIs
should try to develop humane endpoints if severe pain, severe distress, or death is observed.
Guidelines should be in place to euthanize animals 1) when humane endpoints are reached, 2)
when the study objectives have been realized, 3) if it becomes clear that they cannot be
realized, or 4) whenever the degree of suffering is not required or justified by the protocol.

A. Explain how animals with severe responses to treatment will be handled: Animals with
severe distress such as shallow breathing, severe weight loss, inabilty to feed or showing
convulstions or gasping will be euthanized.

B. List the signs of pain or distress that may be severe enough to indicate the need for
euthanization: gasping, severe weight loss, inability to feed, shallow breathing, or showing
severe convusions.
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C. State the method of euthanasia: Animals will be euthanized with CO2 asphyxiation and
cervical dislocation will be used to assure death.

____________________________________________________________________________________
_____________
All animal monitoring forms should be kept in a location accessible to the Attending Veterinarian
and animal care staff. The PI will notify the Attending Veterinarian in a timely manner when
Unanticipated Significant Adverse events are observed. The PI will complete the relevant
monitoring sheet and submit a copy of it to the Animal Care Office in NCNPR.

Include the following information in the Protocol Annual Update Form:
(1) number of compounds used;
(2) number of animals used;
(3) number of animals categorized as something other than the original pain category;
(4) number of animals euthanized after reaching the humane endpoint.
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Data Collection Form for Formalin Assay:
Instructions:
Record number of licking or biting of injected paw for 30
second increments for ten minutes post formalin injection; second period of recording begins fifteen
minutes post formalin injection, again record number of licking or biting of the injected paw in 30 second
increments for forty-five minutes.

Protocol Number:
Date of test:
Animal ID (Mouse Number)

M1

M2

M3

Time (minutes)
0 to 5
5 to 10
10 to 15
15 to 20
20 to 25
25 to 30
30 to 35
35 to 40
40 to 45
45 to 50
50 to 55
55 to 60
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M4

M5

M6

M7

M8

M9

M10

VITA

JESSICA MANKUS
10219 North Trillium Road Mequon, WI 53092 | 414-232-0819 | jessica.mankus@gmail.com
EDUCATION
University of Mississippi
Ph.D. in Pharmaceutical Sciences emphasis in Medicinal Chemistry
2007-2012
Dissertation: Design, Synthesis, and Biological Evaluation of Non-Peptide Neuropeptide FF Ligands
Case Western Reserve University
B.A. in Chemistry and French

2005

Marquette University
Summer courses in physics

2002, 2003

AWARDS
Graduate Student Council Best Senator
2011-2012
PY3 Teaching Assistant of the Year
2009-2010
I.G.E.R.T Fellowship, University of Mississippi
August 2007 – July 2009
Master of Ceremonies, Alpha Chi Sigma Fraternity, Case Western Reserve University August 2004 – May 2005
Dean’s Honors List, Case Western Reserve University
Fall 2001 & Fall 2005
Dean’s High Honors List, Case Western Reserve University
Spring 2005
TEACHING EXPERIENCE
University of Mississippi, University, MS
Teaching Assistant to Medicinal Chemistry course for Pharmacy and Graduate Students 2009-2010
Assisted students in understanding fundamental medicinal chemistry
concepts and graded exams.
Lycée Follereau, Belfort, France
English Teaching Assistant
Incorporated native English speaker into English language and Science
classrooms through various lessons and activities.
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September 2005 – May 2006

PUBLICATIONS
Nonpeptide ligands of neuropeptide FF: current status and structural insights
Jessica V Mankus and Christopher R McCurdy
Future Medicinal Chemistry, 4 (9), 1085-1092.
A Simple Parallel Photochemical Reactor for Photodecomposition Studies.
Xiaobo Chen, Sarah M. Halasz, Eric C. Giles, Jessica V. Mankus, Joseph C.
Johnson, Clemens Burda. Journal of Chemical Education. 83 (2), 265.
RELATED EXPERIENCE
Clemens Burda Research Group, Cleveland, OH
Undergraduate Research Assistant
Carried out quantitative and qualitative analysis of titanium dioxide
nanoparticle solutions related to ultraviolet and visible light absorption;
performed qualitative and quantitative research related to development of
thin film technologies utilizing various nanoparticles.
Columbia St. Mary’s Hospital, Milwaukee, WI
Medical Records Clerk II
Organized and filed pertinent medical information, communicated with
patients and medical professionals, transitioned to electronic medical
records.
Office of Undergraduate Studies, Cleveland, OH
Study Abroad Office Assistant
Aided students in discovering opportunities for study abroad experiences;
corresponded with students abroad to coordinate transitions between abroad
and home universities.
Wood Food Company, Cleveland, OH
Student Administrative Aide
Provided assistance in compiling and cataloging customer service data
related to on-campus dinning services.
LANGUAGES
English — native speaker
French — speak fluently, with a high proficiency in reading and writing.

MEMBERSHIPS
Rho Chi
Alpha Chi Sigma
Iota Sigma Pi
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2012

2006

August 2003 – May 2005

June 2005 – August 2007

2004-2005

2003

